

1 **The role of porcine reproductive and respiratory syndrome (PRRS) virus structural and**
2 **non-structural proteins in virus pathogenesis: A Review**

3
4
5
6
7 Nedzad Music^{1,2}, Carl A. Gagnon^{1,2,3*}

8
9
10 ¹Service de diagnostic; ²Groupe de recherche sur les maladies infectieuses du porc (GREMIP);

11 ³Centre de recherche en infectiologie porcine (CRIP), Faculté de médecine vétérinaire,

12 Université de Montréal, St-Hyacinthe, Québec, Canada.

13
14
15
16
17
18
19 *Address correspondence and reprint requests to

20 Dr Carl A. Gagnon

21 Faculté de médecine vétérinaire

22 Université de Montréal

23 3200 rue Sicotte,

24 St-Hyacinthe, Québec, Canada,

25 J2S 7C6

26 Email: carl.a.gagnon@umontreal.ca

27 Phone: 450-773-8521 (8681)

28 Fax: 450-778-8113

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

ABSTRACT

Porcine reproductive and respiratory syndrome (PRRS) is an economically devastating viral disease affecting swine industry worldwide. Its viral etiological agent, porcine reproductive and respiratory syndrome virus (PRRSV), possesses a RNA viral genome which contains nine open reading frames (ORFs). The ORF1a and ORF1b replicase-associated genes encode the polyproteins pp1a and pp1ab, respectively. The pp1a is processed in nine non-structural proteins (nsp): nsp1 α , nsp1 β , and nsp2 to nsp8. Proteolytic cleavage of pp1ab generates products nsp9 to nsp12. The pp1a cleavage products possess proteolytic activities and are responsible for the processing and cleavage of pp1a and pp1ab into nsp products; whereas nsp9 to nsp12 are involved in virus transcription and replication. The 3' end of the viral genome encodes four minor and three major structural proteins. The GP_{2a}, GP₃ and GP₄ (encoded by ORF2a, 3, and 4), are glycosylated membrane associated minor structural proteins. The fourth minor structural protein, the E protein (encoded by ORF2b), is an unglycosylated and membrane associated protein. The viral envelope contains two major structural proteins: a glycosylated major envelope protein GP₅ (encoded by ORF5), and an unglycosylated membrane M protein (encoded by ORF6). The third major structural protein is the nucleocapsid N protein (encoded by ORF7). All PRRSV non-structural and structural proteins are essential for virus replication, and PRRSV infectivity is relatively intolerant to subtle changes within the structural proteins. Overall, the available data indicate that PRRSV virulence is multigenic and resides in both the non-structural and structural viral proteins. In the following manuscript, the molecular characteristics, biological and immunological functions of the PRRSV structural and non-structural proteins and their involvement in the virus pathogenesis are summarized.

INTRODUCTION

53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75

Porcine reproductive and respiratory syndrome (PRRS) is present worldwide and is the most economically important infectious disease of swine production (Neumann et al., 2005). PRRS disease was first described in the United States in 1987 (Keffaber, 1989; Loula, 1991) and a few years later in the Netherlands (Wensvoort et al., 1991). The disease has many clinical manifestations but the two most prevalent are severe reproductive failure in sows and gilts (characterised by late-term abortions, an increased number of stillborns, mummified and weak-born pigs) (Albina, 1997; Bilodeau et al., 1991; Christianson, 1992; Keffaber, 1989; Loula, 1991; Pol et al., 1991) and respiratory problems in pigs of all ages associated with a non-specific lymphomononuclear interstitial pneumonitis (Albina, 1997; Bilodeau et al., 1991; Collins et al., 1992; Halbur et al., 1996b; Keffaber, 1989; Loula, 1991; Rossow, 1994).

The etiological agent, porcine reproductive and respiratory syndrome virus (PRRSV) was identified in 1991 by investigators in the Netherlands and shortly after in the United States (Benfield et al., 1992; Collins et al., 1992; Wensvoort et al., 1991). The PRRSV is an enveloped, single-stranded positive sense RNA virus, approximately 50–65 nm in diameter that is classified in the order *Nidovirales*, family *Arteriviridae*, genus *Arterivirus* along with equine arteritis virus (EAV), lactate dehydrogenase-elevating virus of mice (LDV), and simian hemorrhagic fever virus (SHFV) (Benfield et al., 1992; Cavanagh, 1997). PRRSV genome is approximately 15 kb in length. The RNA viral genome is capped at the 5' end and polyadenylated at the 3' termini and encodes at least nine open reading frames (ORFs) (Dea et al., 2000a), each of which is expressed via the generation of a 3'-coterminal nested set of subgenomic (sg) mRNAs (Allende et al., 1999; Gorbalenya et al., 2006). ORFs1a and 1b, which take almost 2/3 of the genome,

76 encode non-structural proteins (nsp), such as RNA polymerase, that are required for virus
77 replication (Allende et al., 1999). At least 12 nsps are generated as a result of serial cleavages of
78 two polyproteins expressed from ORF1a and ORF1ab, which RNA is transcribed by a ribosomal
79 frame shift between ORF1a and 1b (Snijder, 1998; Snijder, Meulenberg, 1998). Three N-
80 glycosylated minor envelope proteins (GP_{2a}, GP₃, and GP₄) are translated from ORF2a, 3, and 4
81 and form heterotrimers by disulfide linkage (Wissink et al., 2005). ORF2b, which is completely
82 embedded in ORF2a, encodes another non-glycosylated minor protein named E (Wu et al.,
83 2001). ORF5 encodes the major envelope glycoprotein (GP₅) that forms a heterodimer with the
84 membrane non-glycosylated protein (M) encoded by ORF6 (Mardassi et al., 1996). The viral
85 capsid is composed of only one nucleocapsid protein (N), which is encoded by ORF7 and is
86 highly immunogenic in infected animals (Dea et al., 2000a).

87

88 The virus is genetically, antigenically, and pathogenically heterogenic (Dea et al., 2000a;
89 Meng, 2000). Currently, PRRSV isolates are divided into two distinct genotypes, represented by
90 Lelystad virus (LV) in Europe (Wensvoort et al., 1991) and ATCC VR-2332 in North America
91 (Benfield et al., 1992; Dea et al., 1992). Even though European (EU) and North American (NA)
92 isolates possess several biological and immunological similarities, including a nearly identical
93 genome organization, both strains are genetically and antigenically distinct (Magar et al., 1995;
94 Mardassi et al., 1994a; Nelsen et al., 1999). Sequence analyses have shown approximately a 60%
95 nucleotide identity between the Type I (European - EU) and Type II (North American - NA)
96 genotypes (Allende et al., 1999; Forsberg, 2005; Hanada et al., 2005; Nelsen et al., 1999;
97 Plagemann, 2003). Several studies have shown that a high degree of genetic variability exists
98 within the NA-type of PRRSV (Andreyev et al., 1997; Gagnon, Dea, 1998; Kapur et al., 1996;

99 Meng et al., 1995a; Morozov et al., 1995; Pirzadeh et al., 1998). While early studies suggested
100 that a lower degree of variability might exist in EU PRRSV type (Drew et al., 1997; Suarez et al.,
101 1996b), later studies in some countries, such as Denmark and Italy, have reported a high
102 divergence within EU-type isolates (Forsberg et al., 2001; Forsberg et al., 2002; Madsen et al.,
103 1998; Nielsen et al., 2000; Oleksiewicz et al., 2000). Recently, the emergence of potential highly
104 pathogenic variant of PRRSV as the possible cause for large-scale outbreaks with high mortality
105 in China was reported in 2006 (Li et al., 2007; Tian et al., 2007). It is now obvious that PRRSV
106 isolates showed considerable genetic variation and could be classified in several phylogenetic
107 clusters within each genotypes (Fang et al., 2007; Kiss et al., 2006; Mateu et al., 2006; Yoshii et
108 al., 2005).

109
110 In the following manuscript, the molecular characteristics, biological and immunological
111 functions of the PRRSV structural and non-structural proteins and their involvement in the virus
112 pathogenesis are described.

113

114 **Virus morphogenesis**

115

116 Earlier studies indicate that the N protein forms a spheric icosahedral capsid core of 20-
117 30 nm in diameter, which is surrounded by a lipid envelope containing the viral envelope
118 proteins, yielding a relatively smooth spherical virion of about 60 nm in diameter (Benfield et al.,
119 1992; Dea et al., 2000a; Doan, Dokland, 2003a, b). Recently, Spilman et al. (Spilman et al.,
120 2009) have described the structure of PRRSV virions based on cryo-electron microscopy (EM)
121 analysis and tomographic reconstruction of virions grown in MARC-145 cells. They have
122 reported that the virus has a pleomorphic morphology, a spherical to oval shape with a size

123 ranging from about 50 to 65 nm, a hollow, layered core of around 40 nm diameter and a smooth
124 outer surface studded with a few envelope protein complexes. The structural analysis indicates
125 that the PRRSV core consists of an helical nucleocapsid (see schematic representation in Figure
126 1) wrapped up into a hollow ball (Spilman et al., 2009), unlike previously mentioned studies
127 (Benfield et al., 1992; Dea et al., 2000a; Doan, Dokland, 2003a, b). The latest results are not
128 surprising since other members of the *Nidovirales*, such as coronavirus, have been known to
129 possess a helicoidal capsid. Being an enveloped virus, PRRSV survivability outside the host is
130 affected by temperature, pH and exposure to detergents. It is known that PRRSV can survive for
131 extended intervals at temperatures ranging from -70 to -20^oC (Benfield et al., 1992);
132 nonetheless, viability decreases with increasing temperature. Specifically, recovery of PRRSV
133 has been reported for up to 20 min at 56^oC, 24h at 37^oC, and 6 days at 21 ^oC (Benfield et al.,
134 1992). The PRRSV remains stable at pH ranging from 6.5 to 7.5 but, infectivity is reduced at
135 pH<6.0 or >7.65 (Bloemraad et al., 1994). Detergents are effective at reducing infectivity of the
136 virus and lipid solvents such as chloroform and ether are particularly efficient at disrupting the
137 viral envelope and eliminate infectious virions (Benfield et al., 1992). Even if PRRSV is
138 relatively fragile in the environment, appropriate weather (wind, T^oC, humidity, etc.) may favour
139 the transmission of the virus through aerosols up to 4.7 km distance (Dee et al., 2009).

140

141

Cells pathogenesis

142

143 PRRSV is generally believed to have a very restricted cell tropism both *in vivo* and *in*
144 *vitro*. *In vivo*, the virus mainly infects well-differentiated cells of the monocyte-macrophage
145 lineage, in particular porcine alveolar macrophages (PAM), the primary target cells of virus and

146 interstitial macrophages in other tissues such as heart, thymus, spleen and Peyer's patches,
147 hepatic sinusoids, renal medullary interstitium, and adrenal gland (Beyer et al., 2000; Duan et al.,
148 1997; Halbur et al., 1995; Halbur et al., 1996b). In addition to macrophages, PRRSV RNA and
149 nucleocapsid protein were found by *in situ* hybridization (ISH) and immunohistochemistry,
150 respectively, in testicular germ cells, endothelial cells in the heart, interdigitating cells in the
151 thymus, dendritic cells in the spleen and Peyer's patches (Halbur et al., 1996b; Sur et al., 1997).
152 In experimentally infected gnotobiotic pigs, PRRSV antigens were found in bronchiolar
153 epithelial cells, arteriolar endothelial cells, monocytes as well as interstitial, alveolar, and
154 intravascular macrophages using an immuno-gold-silver immunohistochemical staining (Rossow
155 et al., 1996). PRRSV RNAs and antigens were also found in bronchiolar epithelial cells (Pol et
156 al., 1991), epithelium-like cells of alveolar ducts (Magar et al., 1993), and pneumocytes (Cheon
157 et al., 1997; Pol et al., 1991) in the naturally infected pigs whereas it was not found in these types
158 of cells in the experimentally infected pig (Teifke et al., 2001). Tissues such as lung, lymphoid
159 tissues, Peyer's patches, and kidney were also the preferable organ targets of PRRSV infection
160 (Haynes et al., 1997; Sur et al., 1996).

161 PRRSV was originally isolated on primary cultures of PAMs (Wensvoort et al., 1991)
162 and so far, these cells as well as blood monocytes (Voicu et al., 1994), remain the only porcine
163 cells that can effectively be used for viral propagation. Two non-porcine permissive cell
164 subclones of MA104 monkey kidney cell line, the MARC-145 and CL2621 cells (Bautista et al.,
165 1993; Benfield et al., 1992; Kim et al., 1993) are also routinely used for *in vitro* propagation of
166 wild and vaccine PRRSV strains. Flow cytometric and fluorescence antibody (FA) analyses of
167 PRRSV antigen expression revealed distinct primary and secondary infection phases in MARC-
168 145 cells (Cafruny et al., 2006). PRRSV antigen is randomly expressed in a small amount of

169 cells during the primary phase of infection (up to about 20–22 h p.i.), but the logarithmic
170 infection phase (days 2–3 p.i.) is characterized by secondary spread to clusters of cells. The
171 formation of secondary clusters of PRRSV-infected cells preceded the development of CPE in
172 MARC-145 cells. The primary and secondary PRRSV infection phases are inhibited by
173 colchicine and cytochalasin D, which demonstrate a critical role of the cytoskeleton in viral
174 permissiveness as well as cell-to-cell transmission (Cafruny et al., 2006). Cellular expression of
175 actin also appeared to correlate with PRRSV resistance, suggesting a second role of the actin
176 cytoskeleton as a potential barrier to cell-to-cell transmission (Cafruny et al., 2006).

177 How the virus enters into the cells was firstly reported in 1996 (Kreutz, Ackermann,
178 1996). It was postulated that since the direct fusion of the PRRSV envelope with the cellular
179 membrane was not observed at any time, PRRSV entry most occurs by receptor-mediated
180 endocytosis. In 1998, this hypothesis was confirmed (Duan et al., 1998) and a PRRSV receptor
181 was identified on PAM by generation of PAM-specific monoclonal antibodies. Several viral
182 receptors for PRRSV have been described, including heparin sulphate for binding, sialoadhesin
183 for binding and internalization, and vimentin (Delputte, Nauwynck, 2004; Delputte et al., 2007a;
184 Delputte et al., 2007b; Delputte et al., 2002; Kim et al., 2006). However, additional factors are
185 needed because the expression of both receptors in non-permissive cells results in virus
186 internalization but not in virus uncoating and productive infection. Recently, a molecule that is
187 expressed exclusively on cells of a monocytic lineage the CD163, has been identified as a
188 possible cellular receptor for PRRSV (Calvert et al., 2007; Patton et al., 2009; Van Gorp et al.,
189 2008). Furthermore, susceptibility of macrophages to PRRSV infection was previously shown to
190 be associated with high expression of CD163 (Lopez-Fuertes et al., 2000). The role of CD163
191 and its interaction with sialoadhesin during PRRSV infection of macrophages were investigated

192 (Van Gorp et al., 2008). Both sialoadhesin and CD163 are involved in infection of macrophages
193 with different PRRSV strains (Van Gorp et al., 2008). Thus, sialoadhesin is confirmed as a
194 PRRSV internalization receptor and CD163 is shown to be involved in PRRSV infection,
195 probably during uncoating (Van Gorp et al., 2008). Finally, non-permissive cells expressing both
196 sialoadhesin and CD163 are clearly more susceptible to PRRSV infection and produce more
197 virus (10 to 100 time more) compared with cells expressing only CD163 (Van Gorp et al., 2008).
198 The interaction between the viral glycoproteins and CD163 receptor were characterized using
199 co-immunoprecipitation (co-IP) assay using monospecific antibodies (Das et al., 2010). It was
200 found that the GP_{2a} and GP₄ proteins interact with the CD163 molecule (Das et al., 2010). The
201 carboxy-terminal 223 residues of CD163 molecule are not required for interactions with either
202 the GP_{2a} or the GP₄ protein, although these residues are required for conferring susceptibility to
203 PRRSV infection in BHK-21 cells. Overall, it was postulated that the GP₄ protein is critical for
204 mediating interglycoprotein interactions and along with GP_{2a}, serves as the viral attachment
205 protein that is responsible for mediating interactions with CD163 for virus entry into susceptible
206 host cell (Das et al., 2010). The CD151 molecule was identified by RNA-ligand screening of a
207 MARC-145 cell expression library to be a PRRSV 3' UTR RNA-binding protein
208 (Shanmukhappa et al., 2007). The CD151 is a member of the tetraspanin superfamily, which has
209 several cellular functions that include cell signaling, cell activation and platelet aggregation
210 (Fitter et al., 1999; Hasegawa et al., 1998; Sincock et al., 1999). Transfection of CD151 rendered
211 BHK-21, a non-susceptible cell line, susceptible to PRRSV infection. The transfection of siRNA
212 against CD151 inhibited PRRSV infection into MARC-145 cells. Additionally, polyclonal anti-
213 CD151 antibody (Ab) completely blocked PRRSV infection into MARC-145 cells

214 (Shanmukhappa et al., 2007). These results suggest that CD151 plays a critical role in PRRSV
215 infection *in vitro*.

216 PRRSV induces apoptosis both *in vitro* and *in vivo* (Choi, Chae, 2002; Kim et al., 2002;
217 Labarque et al., 2003; Miller, Fox, 2004; Sirinarumitr et al., 1998; Suarez et al., 1996a; Sur et al.,
218 1997; Sur et al., 1998). PRRSV infection of both MARC-145 cells and PAM results in apoptosis
219 which is characterized by morphological changes, DNA fragmentation and specific caspase
220 activation. PRRSV seem to be able to induce apoptosis directly (in infected cells) or indirectly
221 (in bystander non infected cells) in infected animals. For example, GP₅ protein of PRRSV has
222 been shown to be an apoptosis inducer in GP₅ expressing cells (Gagnon et al., 2003; Suarez et
223 al., 1996a). However, others have shown that PRRSV induces apoptosis mostly in uninfected
224 bystander cells both *in vitro* and *in vivo* and that the majority of apoptotic cells in lung lavages,
225 lungs, and lymphoid tissues are not positive for PRRSV antigens and RNA (Choi, Chae, 2002;
226 Kim et al., 2002; Labarque et al., 2003; Miller, Fox, 2004; Sirinarumitr et al., 1998; Suarez et al.,
227 1996a; Sur et al., 1997; Sur et al., 1998). It was reported that alveolar macrophages from
228 PRRSV-infected pigs show a significantly increased apoptotic rate (22–34%) compared to
229 porcine circovirus 2 infected alveolar macrophages (3%) (Chang et al., 2005). Given the fact that
230 only 5–10% of alveolar macrophages were PRRSV-infected, these authors suggested that TNF- α
231 or GP₅ released from PRRSV-infected cells induce apoptosis in non-infected cells. Another
232 study from the same group demonstrated that increased FasL expression in PRRSV-infected
233 macrophages caused apoptosis in co-cultured swine splenic lymphocytes (Chang et al., 2007). A
234 previous report showed that the majority of apoptotic cells are characterized by both early and
235 late apoptosis markers (Lee, Kleiboeker, 2007). Ultimately, these authors demonstrated that
236 PRRSV induce apoptosis through a mitochondrial-mediated pathway. Two oppositely directed

237 sets of reactions are switched on in PRRSV-infected macrophages *in vitro*: at first, the balance is
238 driven towards anti-apoptosis, but finally, PRRSV-infected macrophages die by apoptosis
239 (Costers et al., 2008). Both anti- and pro-apoptotic effects were not only observed in PRRSV-
240 infected macrophages, but also in PRRSV-infected MARC-145 cells (Costers et al., 2008).

The nucleocapsid protein (N)

241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262

The unglycosylated N protein possesses 123 to 128 amino acids (aa) depending on the genotype of the strains (NA versus EU, respectively) with a molecular weight of 15 kDa, and is encoded by ORF7 viral gene (Figure 2). The N protein of PRRSV is a multifunctional protein (Table 1). It is a basic protein with an isoelectric point of 10.4 and was shown to be a serine phosphoprotein (Wootton et al., 2002). Given that EAV and coronavirus nucleocapsid proteins are also phosphoproteins (Laude et al., 1995; Zeegers et al., 1976), phosphorylation of the nucleocapsid protein appears to be a common feature of nidoviruses. Phosphorylation of the N protein occurs, at position 120 (Figure 3) in PRRSV-infected cells and also in ORF7 gene-transfected cells, where the N protein is synthesized in the absence of other viral components (Wootton et al., 2002). Evolutionary conservation of this post translational modification suggests that phosphorylation of the N protein may be of significant biological importance for the virus and, therefore, it warrants further investigation. Multifunctional proteins are often regulated by phosphorylation, and this phenomenon is particularly common to positively charged, nucleic acid binding proteins that make up the nucleocapsids of the coronavirus (Laude et al., 1995; Yoo et al., 1992), hepatitis B virus (Roossinck, Siddiqui, 1987), influenza virus (Arrese, Portela, 1996; Yang, Zhang, 1999), rabies virus (McNabb, Courtney, 1992; Yang, Zhang, 1999), herpes simplex virus (McNabb, Courtney, 1992), and parvovirus (Maroto et al., 2000). Since it is well documented that phosphorylation is involved in regulating the activities of proteins at multiple levels, including nucleic acid binding, oligomerization, and nuclear transport, phosphorylation may likewise affect these properties of the PRRSV N protein.

263 The N protein is highly immunogenic in pigs (Loemba et al., 1996; Meulenberg et al.,
264 1995a, b) and in mice (Drew et al., 1995; Nelson et al., 1993; Rodriguez et al., 1997; van
265 Nieuwstadt et al., 1996). Several groups have generated anti-N monoclonal antibodies (mAbs)
266 that recognise epitopes specific to or shared by NA and EU isolates (Dea et al., 1996; Drew et
267 al., 1995; Meulenberg et al., 1998; Nelson et al., 1993; Wootton et al., 1998). Based on the
268 immunoreactivity of N protein deletion mutants with panels of N-specific mAbs, five domains of
269 antigenic importance have been identified for a reference NA strain, four of them being localized
270 at aa 30 to 52, 37 to 52, 69 to 112, and 112 to 123, respectively (Figure 3). Other mAbs revealed
271 the presence of a common conformational antigenic site localised in the central region (aa 52–
272 69) of the protein (Rodriguez et al., 1997; Wootton et al., 1998). Mutational analysis revealed
273 that the carboxyl-terminus of N plays a critical role in the formation of the conformational
274 epitopes, and a domain comprised of the 11 C-terminal-most aa (residues 112 to 123) (Figure 3)
275 was shown to be essential for binding of N-specific conformation-dependent mAbs (Meulenberg
276 et al., 1998; Wootton et al., 2001; Wootton et al., 1998). The region between aa 37 and 52 is well
277 conserved among isolates of both genotypes and is the most hydrophilic region of the protein
278 (Figure 3). None of the N-specific mAbs have been found to be associated with virus
279 neutralisation. Four distinct antigenic domains were identified for the reference EU LV strain
280 (Meulenberg et al., 1998). Three sites, designated A–C, contain linear epitopes, and these were
281 mapped between aa 2–12, 25–30, and 40–46, respectively. However, the fourth region,
282 designated domain D, contains conformation-dependent or discontinuous epitopes that are
283 (partially) composed of aa 51–67 and 80–90 (Meulenberg et al., 1998). The early immunological
284 response generated in PRRSV-infected pigs is directed mainly against the N protein, and this
285 response, which can be detected as early as one week postinfection (Loemba et al., 1996),

286 declines at a much lower rate than the one directed against the major structural proteins M and
287 GP₅ (Yoon et al., 1995). Since the majority of antibodies produced during PRRSV infection in
288 pigs are directed against the N protein, for which major antigenic determinants are highly
289 conserved, the N protein has been targeted as a suitable candidate for the detection of virus-
290 specific antibodies and diagnosis of the disease.

291 One of the fundamental role of the viral capsid protein is to provide a protective
292 enclosure for the viral genome during the extracellular phase of the virus life cycle. The N
293 protein is the sole component of the viral capsid and interacts with itself through covalent and
294 non-covalent interactions (Wootton, Yoo, 2003). NA PRRSV N protein contains three highly
295 conserved cysteine residues at aa positions 23, 75 and 90. Systematic mutation of the three
296 cysteine residues at positions 23, 75, and 90, either alone or in combination, revealed that the
297 cysteine at position 23 (Figure 3) is involved in the formation of intermolecular disulfide bonds
298 between N proteins (Wootton, Yoo, 2003). Subsequently, the functional significance of the N
299 cysteine residues for PRRSV infectivity was assessed using an infectious cDNA clone (Lee et
300 al., 2005). Each cysteine at positions 23, 75, and 90 was replaced with serine and the individual
301 mutation was incorporated into the cDNA clone such that three independent cysteine mutants
302 were constructed. When transfected, the wild type and C75S clones induced cytopathic effects
303 and produced infectious virus with indistinguishable plaque morphology. In contrast, the C23S
304 mutation completely abolished infectivity of the clone, indicating that C23-mediated N protein
305 homodimerization plays a critical role in PRRSV infectivity (Lee et al., 2005). The C90S
306 mutation also appeared to be lethal for virus infectivity. This is an unexpected observation since
307 cysteine 90 is irrelevant to the N protein homodimerization and because cysteine 90 is absent
308 among the EU PRRSV isolates. The EU isolates of PRRSV contain only two cysteines at

309 positions 27 (involved in the formation of intermolecular disulfide bonds between N proteins)
310 and 76. The N protein dimer (Figure 1) was shown to be stable both in the presence and absence
311 of intermolecular disulfide linkages, indicating that non-covalent interactions also play a role in
312 dimerization. Using a series of N protein deletion mutants fused to glutathione S-transferase
313 (GST) in a pull-down assay, aa 30 to 37 were shown to be essential for non-covalent N-N
314 interactions (Figure 3). Furthermore, since RNase A treatment markedly decreased N protein-
315 binding affinity, it appears that at least *in vitro*, RNA may be involved in bridging N-N
316 interactions. Upon translation in the cytoplasm, the N protein interacts with itself via non-
317 covalent binding. As N is transported to the lumen of the endoplasmic reticulum (ER) and the
318 Golgi complex, where its environment is oxidative and PRRSV maturation occurs, the N-N
319 interaction becomes disulfide linked (Snijder, Meulenberg, 1998; Wootton, Yoo, 2003).
320 Together, these findings demonstrate that the N protein possesses self-associative properties, and
321 these likely provide the basis for PRRSV nucleocapsid assembly.

322 PRRSV, like several other RNA viruses, replicates in the cytoplasm (Benfield et al.,
323 1992; Mardassi et al., 1994b). However, a fraction of the N protein has been found to localize
324 into the nucleus and nucleolus during infection of PAM and MARC-145 cells (Rowland et al.,
325 1999). Two conserved aa stretches, which are similar to sequences that resemble two classical
326 types of nuclear localization signal (NLS), have been identified (Figure 3) in the N protein at aa
327 positions 10 to 13 and 41 to 47 (NLS-1 or cryptic NLS and NLS-2 or functional NLS,
328 respectively) (Rowland et al., 1999; Rowland et al., 2003). The inactivation of NLS-1 by site-
329 directed mutagenesis or the deletion of the first 14 aa did not affect N protein localization to the
330 nucleolus. The substitution of key lysine residues with uncharged amino acids in NLS-2 blocked
331 nuclear/nucleolar localization. Site-directed mutagenesis identified the KKNKK sequence as

332 forming the core localization domain within NLS-2. The NLS-2 was shown to be functional and
333 sufficient for the translocation and accumulation of N in the nucleolus (Rowland et al., 1999;
334 Rowland et al., 2003; Rowland, Yoo, 2003). Proteins that localize to the nucleolus typically
335 possess a nucleolar localization signal (NoLS) motif. A region covering aa 41–72 (Figure 3) was
336 found to contained a NoLS sequence (Rowland et al., 2003; Yoo et al., 2003). The nucleolar
337 localization of the N protein has also been reported for EAV (Tijms et al., 2002) and for several
338 members of the *Coronaviridae* (Chen et al., 2002; Wurm et al., 2001). The arterivirus and
339 coronavirus N proteins, when expressed alone or fused to the red-shifted EGFP, localize to the
340 nucleolus, demonstrating that translocation across the nuclear pore complex (NPC) and
341 accumulation in the nucleolus are independent of other viral proteins (Hiscox et al., 2001;
342 Rowland, Yoo, 2003; Tijms et al., 2002; Wurm et al., 2001).

343 Since the Golgi apparatus is thought to be the maturation site of arteriviruses, it has been
344 postulated that the PRRSV N protein plays dual roles during virus infection; a virion structural
345 role in the cytoplasm and a non-structural role in the nucleus and/or nucleolus. The N protein
346 NLS-null PRRSV-infected pigs had a significantly shorter mean duration of viremia than wild-
347 type-infected pigs and increased production of neutralizing antibodies in infected pigs (Lee et al.,
348 2006a; Lee et al., 2006b). However, MARC-145 cells infected with the NLS-null mutant virus
349 produced cytopathology indistinguishable from that of wild-type virus, but with lower viral titers
350 and smaller size plaques formations (Lee et al., 2006a; Lee et al., 2006b). Furthermore the N
351 protein nuclear localization is associated with the virulence of PRRSV since modification in the
352 NLS caused attenuation of the virus (Lee et al., 2006a; Lee et al., 2006b; Pei et al., 2008)
353 suggesting that the N protein localization in the nucleus may play a role in viral pathogenesis.
354 The precise mechanism of N protein trafficking within a cell and to the nucleolus is unknown,

355 although N protein has been shown to interact with the small nucleolar RNA (snoRNA)-
356 associated protein fibrillarin and thus may potentially localise to the nucleolus via this interaction
357 (Yoo et al., 2003). Using an *in vitro* pull-down assay, the N protein was able to bind importin- α
358 and importin- β nuclear transport proteins (Rowland, Yoo, 2003). The formation of an N
359 protein/importin complex using *in vitro* translated N demonstrates that N protein binding is
360 independent of other viral proteins. The GST-bead pull-down assay was used, to determine if the
361 principal export shuttle protein, the chromosome region maintenance 1 (CRM1), could bind N
362 protein (Rowland, Yoo, 2003). Radiolabeled N protein, prepared from virus infected cells or by
363 *in vitro* translation, was incubated with the GST-human CRM1 fusion protein immobilized on
364 glutathione-Sepharose beads. The results showed that CRM1 indeed bound to PRRSV N protein
365 (Rowland, Yoo, 2003). On the opposite (Tijms et al., 2002), it was reported that EAV N protein
366 localized to all nucleoli when cells were treated with leptomycin B (LMB), an inhibitor of
367 CRM1-dependent export. In conclusion, the N protein nuclear transport is importin- α/β -based
368 and CRM1-dependent. It is interesting that a virion structural protein from a cytoplasm-
369 replicating RNA virus interacts with a host cell transcription factor. It was shown previously that
370 the PRRSV N protein can interact with fibrillarin and co-localizes with fibrillarin in the
371 nucleolus (Yoo et al., 2003). For NA N protein, eight amino acids (IAQQNQSR) at positions 30
372 to 37 were identified as the binding domain with fibrillarin. Interestingly, this string of aa was
373 previously mapped as the region which participated in the formation of the N-N interaction
374 (Wootton, Yoo, 2003). This region corresponds to a relatively hydrophilic region of N and forms
375 part of the conformational epitope recognized by mAb SDOW17 (Wootton et al., 2001). The
376 interaction of viral capsid with the cellular transcription factor implicates a possible regulation of
377 host cell gene expression by the N protein during PRRSV infection (Song et al., 2009).

378 Localization of the virus capsid proteins and replication proteins in the nucleus and/or nucleolus
379 appears to be an emerging feature of positive strand RNA viruses (Song et al., 2009). The reason
380 why positive strand RNA virus capsid proteins localize in the nucleolus is unknown, and several
381 hypotheses have been proposed including; i) as part of a cellular defense mechanism to sequester
382 viral proteins away from sites of virus replication and assembly; ii) to recruit nucleolar proteins
383 to facilitate virus replication; iii) to usurp cellular processes by disrupting the nucleolar
384 proteome; or iv) only because the viral protein contains motifs which mimic nucleolar
385 localization signals (NoLSs) (Hiscox, 2002, 2003, 2007; Rowland, Yoo, 2003; Uchil et al., 2006;
386 Weidman et al., 2003).

387 In resume, the N protein is the sole component of the PRRSV capsid. In addition, it is a
388 highly immunogenic protein which makes it a suitable candidate for the detection of virus-
389 specific antibodies and subsequently for the diagnosis of the disease. The PRRSV N protein
390 plays dual roles during virus infection; 1) a virion structural function and 2) a non-structural role
391 in the nucleus/nucleolus, indicating that the N protein localization in these compartments may
392 play a fundamental role in viral pathogenesis such as the regulation of cell genes expression. In
393 a near future, further studies will have to be conducted to elucidate the role of the N protein in
394 the nucleus/nucleolus and will certainly give new interesting insight on the cell pathogenesis of
395 PRRSV.

The membrane envelope protein (M)

396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418

The M protein is an 18 to 19 kDa class III membrane protein composed of 174 and 173 aa for NA and EU genotypes, respectively, and is encoded by ORF6 viral gene (Figure 2). Its membrane structure consists of a core of three successive membrane-spanning domains preceded by an ectodomain of 13–18 amino acids and followed by a C-terminal endodomain of 81–87 aa (de Vries et al., 1992; Faaberg, Plagemann, 1995; Meulenberget al., 1995a, b). As demonstrated experimentally for the closely related M protein of coronaviruses (de Haan et al., 1998; Vennema et al., 1996), the arteriviral M protein is likely to play a key role in virus assembly and budding (Table 1). The M protein is unglycosylated and is the most conserved structural protein of arteriviruses and PRRSV (Mardassi et al., 1995a, b; Meulenberget al., 1993b). In the virion, the GP₅ and M proteins are found as a disulfide-linked heterodimer (Figure 1), which is an essential requirement for virus infectivity for arteriviruses (Delputte et al., 2002; Faaberg et al., 1995a; Mardassi et al., 1996; Snijder et al., 2003). These disulfide-linked complexes are formed in the endoplasmic reticulum (ER) of infected cells preceding or during virus assembly (de Vries et al., 1995; Dobbe et al., 2001; Faaberg et al., 1995a; Mardassi et al., 1996).

The GP₅–M heterodimerization was shown to be essential for virus infectivity and it is a key step in the assembly of EAV virion (Snijder et al., 2003). The disulfide bond between PRRSV GP₅ and M proteins presumably occurs between cysteine residues at positions 50 and 8 (EU isolates), respectively (Verheije et al., 2002). Mutating either one of these residues resulted in a complete block of particle production (Verheije et al., 2002), indicating that the covalent association of GP₅ and M is crucial for virus assembly. Using a reverse genetics approach it was shown that the two major envelope proteins, the GP₅ and M proteins are essential for the

419 formation of EAV particles (Wieringa et al., 2004). Noteworthy, it is interesting to point out that
420 the disulfide-linked ectodomains of the LDV heterodimer VP-3P-M protein (VP-3P is the GP₅
421 homolog protein of LDV) have been proposed to stabilize the virus attachment site for
422 interaction with a host cell receptor (Faaberg et al., 1995b).

423 The development of neutralizing antibodies was reported in mice inoculated with a
424 *Mycobacterium bovis* bacille Calmette-Guérin (BCG) expressing the M protein (Bastos et al.,
425 2002). More recently, three replication-defective recombinant adenoviruses were developed as
426 potential vaccine against PRRSV and evaluated in a mouse model (Jiang et al., 2006a). Three
427 groups of BALB/c mice were inoculated subcutaneously twice at 2-week intervals with the
428 recombinants adenovirus expressing PRRSV GP₅ (rAd-GP₅), M (rAd-M), and M-GP₅ fusion
429 protein (rAd-M-GP₅). The results showed that the mice inoculated with recombinant
430 adenoviruses developed PRRSV-specific antibodies and a cellular immune response at 2 weeks
431 post second inoculation (Jiang et al., 2006a). However, only mice immunized with rAd-M-GP₅
432 developed significantly higher titers of neutralizing antibodies to PRRSV and produced stronger
433 lymphocyte proliferation responses compared to mice immunized with rAd-M or rAd-GP₅ (Jiang
434 et al., 2006a). In conclusion, the presence of M protein increases the immune response against
435 GP₅ by increasing the cellular immune response and the productions of neutralizing antibodies
436 (Abs).

437 Using Pepscan technology and sera of 15 experimentally NA PRRSV infected pigs, the
438 B-cell linear epitopes were identified in some of the non-structural proteins and all of the
439 structural proteins (de Lima et al., 2006). Overall, the highest degree of immunogenicity and
440 conservation was exhibited by two epitopes identified in the C-terminal end of the M protein
441 (ORF6) (de Lima et al., 2006). These immunoreactive peptides are located at position 151–174

442 which corresponds to the C-terminus end of the endodomain of M protein. In order to confirm
443 the results demonstrated by the sequence alignment, the reactivity of both synthetic peptides was
444 further tested with sera from pigs experimentally infected with several other NA PRRSV strains
445 and all sera samples were confirmed positive. It was found that the peptide containing the
446 residues A¹⁶¹VKQGVVNLVKYAK¹⁷⁴ can be particularly useful for diagnostic purposes and one
447 attractive candidate as a negative serological marker in a PRRSV vaccine (de Lima et al., 2006).
448 Earlier study (Oleksiewicz et al., 2002), using phage-displayed technology, also reported the
449 identification of one epitope localized in the large putative endodomain of the M protein (aa
450 138–159) of a EU PRRSV strain. This epitope was recognized by sera collected very late in
451 infection (Oleksiewicz et al., 2002).

452

The major glycosylated envelope viral protein (GP₅)

453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475

One of the most variable regions of the PRRSV genome is the ORF5 gene (Figure 2) which encodes the GP₅ glycoprotein (Andreyev et al., 1997; Mardassi et al., 1995a; Meng et al., 1995b). The GP₅ is a transmembrane protein of approximately 25 kDa (Dea et al., 2000a; Gagnon et al., 2003; Meulenberg et al., 1995a). The GP₅ protein contains an N-terminal putative signal sequence which is assumed to be cleaved (Mardassi et al., 1995a; Meng et al., 1995b; Meulenberg et al., 1995a; Murtaugh et al., 1995) of approximately 30 aa, followed by an ectodomain of approximately 35 residues with a variable number of potential N-glycosylation sites, a long hydrophobic region of about 60 residues that is presumed to span the membrane one to three times, and a hydrophilic C terminus of approximately 70 aa (Meulenberg et al., 1995a). Some authors have suggested that it possesses two membrane-spanning motifs between residues 65–130 and 170–190 (Dea et al., 2000a) while others have proposed that the protein may span the membrane three times (Meulenberg, 2000). GP₅ is one of the most variable (Table 1) structural protein in the PRRSV genome (Mardassi et al., 1995a; Meng et al., 1995b) with the highest degree of diversity within one genotype: 89–94% identity among NA isolates and 87.1–99.25% identity among EU isolates (Andreyev et al., 1997; Suarez et al., 1996b). It is important to mention that some other parts of the genome also possess considerable degree of variability such as ORF3 gene and the nsp2 protein (Fang et al., 2004; Oleksiewicz et al., 2000). Interestingly, it was hypothesized that PRRSV exists during natural infection as a quasispecies distribution of related genotypes and that this variation could account for the inability of traditional approaches such as vaccination to control PRRS adequately. It was also found that multiple variants of PRRSV can exist simultaneously on farms and within individual animals

476 during natural infection (Goldberg et al., 2003). Nonetheless, the existence of quasispecies could
477 be responsible for the emergence of viruses with novel clinical and/or antigenic properties and
478 reduce the efficiency of vaccination.

479 The GP₅ protein of PRRSV is one of the most important structural proteins (Table 1)
480 exposed on the surface of the virion and contains epitopes involved in virus neutralisation and
481 protection (Ansari et al., 2006; Gonin et al., 1999; Pirzadeh, Dea, 1997, 1998; Wissink et al.,
482 2003). Monoclonal Abs (mAbs) against GP₅ are able to neutralize virus infectivity in cell culture
483 (Gonin et al., 1999; Pirzadeh, Dea, 1997; Weiland et al., 1999; Zhang et al., 1998). *In vivo*, most
484 of the neutralizing antibodies that could be found in infected animals are predominantly directed
485 against GP₅ (Gonin et al., 1999). Pigs vaccinated with genetically engineered vaccines that
486 express the GP₅ protein could produce neutralizing antibodies against PRRSV (Jiang et al.,
487 2006b; Kheyar et al., 2005; Pirzadeh, Dea, 1998) and the pigs could be partially protected
488 against generalized viremia and lung lesions development following PRRSV challenge
489 (Pirzadeh, Dea, 1998; Qiu et al., 2005; Xue et al., 2004). Pregnant gilts treated with
490 hyperimmune serum from convalescent pigs are fully protected from reproductive failure upon
491 homologous challenge which suggests that IgG can provide a protective immunity *in vivo*
492 (Osorio et al., 2002). On the other hand, other experiments have shown that GP₅ antibodies alone
493 do not provide full protection against PRRS disease even after homologous challenge (Pirzadeh,
494 Dea, 1998; Plana-Duran et al., 1997a). Consequently, GP₅ is not the only determinant of
495 protective immunity, and is particularly unlikely to be the determinant of cross protection in case
496 of heterologous challenge since it is highly variable.

497 Hydropathy profiles of the GP₅ protein predict that it possesses a signal sequence (aa 1–
498 32), an ectodomain (aa 33–63), a transmembrane region (aa 64–134), and an endodomain (aa

499 135–200), although there are some differences in the length of the predicted signal sequence
500 between the NA and EU strains of PRRSV (Figure 4) (Andreyev et al., 1997; Dea et al., 2000a;
501 Meng et al., 1995b; Meulenberg et al., 1995a; Stadejek et al., 2002; Yang et al., 1998).
502 Comparison of the nt and aa sequences of the GP₅ protein of a large number of PRRSV strains
503 from NA and EU strains identified a hypervariable region (aa 32–40), two variable regions (aa
504 57–70 and 121–130) and three conserved regions (aa 41–56, 71–120 and 131–200), and multiple
505 potential N-glycosylation sites (Andreyev et al., 1997; Faaberg, Plagemann, 1995; Key et al.,
506 2001; Meng et al., 1995b; Plagemann, 2004; Plagemann, 1996; Stadejek et al., 2002; Yang et al.,
507 1998). The first potential N-glycosylation site is located in the hypervariable region (N32 or N33
508 or N34) of the GP₅ ectodomain, and it is present in many but certainly not all NA and EU strains
509 of PRRSV (Figure 4). The second and third potential N-glycosylation sites are located at either
510 aa residues N44 and N51 (NA strains of PRRSV) or N46 and N53 (EU strains of PRRSV), and
511 are highly conserved among field strains of PRRSV. In addition to these three N-glycosylation
512 sites some NA isolates (U.S. ATCC VR-2332 and Quebec IAF-Klop reference strains) have an
513 additional (fourth) potential N-glycosylation site at aa residue N30 (Dea et al., 2000a; Key et al.,
514 2001; Plagemann, 2004). Using peptide mapping it was shown that the major neutralization
515 epitope of PRRSV is located into the middle of the GP₅ ectodomain (aa 36–52) (Plagemann et
516 al., 2002). Using swine polyclonal antisera and mouse mAbs, the non-neutralizing (epitope A)
517 and neutralizing epitopes (epitope B) in the ectodomain of the GP₅ protein of PRRSV were
518 identified (Ostrowski et al., 2002). Epitope B was recognized by a neutralizing mAb and high
519 SN-titered swine antisera. Neutralizing epitope B includes aa 37–45 of GP₅ and is conserved
520 among PRRSV isolates, but it is not immunodominant (Figure 4). In contrast, the non-
521 neutralizing epitope A includes aa residues 27–30, and is hypervariable and immunodominant

522 (Figure 4). Interestingly, PRRSV-infected pigs first develop antibodies against epitope A and
523 neutralizing antibodies against epitope B only appear later. Thus, the immunodominant epitope
524 A may act as a decoy and so delay the neutralizing antibody response against epitope B, although
525 the true significance of this potential mechanism of immune evasion of field strains of PRRSV
526 remains uncertain (Plagemann, 2004). The presence of N-glycans in and around epitope B may
527 also reduce the immunogenicity of this critical neutralization determinant in the GP₅ protein,
528 consistent with the low immunogenicity of PRRSV virions into mice and their failure to develop
529 a strong neutralizing antibody response to the virus. Using the site-directed mutagenesis and
530 pepscan analysis it was shown that the aa residue at position 24 of the GP₅ signal sequence of an
531 EU strain of PRRSV was critical for a neutralizing mAb recognition; specifically, the presence
532 of a proline residue at position 24 promotes cleavage of the signal peptide at residues 28 and 29
533 rather than 32 and 33 (Wissink et al., 2003). They also demonstrated a second neutralization
534 epitope recognized by mAbs that includes aa 29–35 of GP₅. Together these data suggest that the
535 major neutralization determinants of PRRSV are located in the N-terminal portion of the GP₅
536 protein, and that inherent properties of the protein such as “decoy” epitopes and heterogeneous
537 glycosylation that obscures the critical neutralization site(s) can impede and decrease the
538 humoral immune response against PRRSV GP₅.

539 Several studies provide evidence that glycosylation of GP₅ of PRRSV play an important
540 role in escaping or minimizing virus-neutralizing antibody response by a N-glycan-shielding
541 mechanism (Johnson et al., 2003; Wei et al., 2003). This N-glycan neutralisation shielding
542 mechanism is also observed in LDV (Chen et al., 2000) and others viruses such as hepatitis B
543 virus (HBV) (Lee et al., 2003), simian immuno deficiency virus (Reitter, Desrosiers, 1998),
544 Influenza virus (Skehel et al., 1984), and human immuno deficiency virus (HIV) (Wei et al.,

2003). Biochemical studies indicate that the mature GP₅ contains high-mannose-type sugar moieties at all three N-glycosylation sites (N34, N44, and N51) (Figure 4). The mutation involving residue N44 did not result in infectious progeny production, indicating that N44 is the most critical aa residue for infectivity. Viruses carrying mutations at N34, N51, and N34/51 grew to lower titers than the wild-type (wt) PRRSV (Ansari et al., 2006). All mutated viruses exhibited enhanced sensitivity to neutralization by swine sera. Furthermore, inoculation of pigs with the mutant viruses induced significantly higher levels of neutralizing antibodies against the mutants as well as the wt PRRSV, suggesting that the loss of N-glycan residues in the ectodomain of GP₅ enhances both the sensitivity of these viruses to *in vitro* neutralization and the immunogenicity of the nearby neutralization epitope (Ansari et al., 2006). Similar results have been obtained in regards to GP₅ of the EU reference strain LV and demonstrate that the N-glycan moiety of the N46 glycosylation site (which corresponds to the N44 in the case of NA strains) is required for virus particle production (Wissink et al., 2004). Interestingly, the authors also found that the N-linked glycans normally located at the N53 of GP₅ (which corresponds to the N51 for NA strains) and present on the GP_{2a} protein are not essential for particle formation. Furthermore, the lack of N-linked oligosaccharides on GP_{2a} and at N53 of GP₅ did not significantly affect the infectivity of the viruses compared to GP₅ N46 mutant (Wissink et al., 2004). In conclusion, preventing the glycosylation of the GP₅ protein at position N44 and N46, respectively for NA and EU strains, had dramatic effects on virion production and virus infectivity (Wissink et al., 2004). The N-linked glycosylation, in general, is important for correct folding, targeting, and biological activity of proteins (Helenius, 1994; Helenius, Aebi, 2001, 2004). In many enveloped viruses, the envelope proteins are modified by the addition of sugar moieties and the N-linked glycosylation of envelope protein plays diverse functions such as receptor binding, membrane

568 fusion, penetration into cells, and virus budding (Braakman, van Anken, 2000; Doms et al.,
569 1993). Furthermore, it has become evident that glycosylation of viral envelope proteins is a
570 major mechanism for viral immune evasion and virus persistence which has been used by several
571 different enveloped viruses to escape, block, or minimize the virus-neutralizing antibody
572 response. Examples of this effect have now been reported for PRRSV and several other viruses
573 such as arterivirus LDV (Chen et al., 2000), simian immunodeficiency virus (Reitter, Desrosiers,
574 1998), hepatitis B virus (Lee et al., 2003) influenza virus (Skehel et al., 1984).

575 GP₅ forms an heterodimeric complex with the M protein (Figure 1) via disulfide bound
576 (Mardassi et al., 1996; Snijder et al., 2003). The disulphide bond between GP₅ and M occurs
577 between Cys50 and Cys8 (EU isolates) of the respective proteins (Verheije et al., 2002).
578 Mutating either one of these residues resulted in a complete block of particle production
579 (Verheije et al., 2002), indicating that the covalent association of GP₅ and M is crucial for virus
580 assembly (Verheije et al., 2002). The PRRSV GP₅-M complexes were shown to interact with
581 heparin (Delputte et al., 2002), suggesting a role in regards to attachment of virus to alveolar
582 macrophages. Thereafter, it has been proposed that the GP₅ is involved in the entry of virus into
583 the host cells, presumably by interacting with the macrophages host cell receptor sialoadhesin
584 (Delputte, Nauwynck, 2004). The role of GP₅ in receptor recognition is supported by the
585 presence of a major neutralization epitope in the N-terminal ectodomain (Ostrowski et al., 2002),
586 implying a central role for the GP₅ ectodomain in the infection process.

587 The GP₅ protein is involved in the apoptosis phenomenon induce by PRRSV (Gagnon et
588 al., 2003; Suarez et al., 1996a). The apoptotic inducing region of GP₅ has been mapped to the
589 first N-terminal 119 aa (Fernandez et al., 2002). During apoptosis in PRRSV infected MARC-
590 145 cells and in MARC-145 cells expressing the GP₅ protein, specific apoptotic enzymes, are

591 activated, like caspase-3 which is a hallmark of apoptosis pathways induction (Gagnon et al.,
592 2003).

593 The MARC-145 and HeLa cells were transfected with ORF4 and ORF5 of PRRSV and
594 differential gene expressions were studied using microarray chips embedded with 1718 human-
595 expressed sequence tags (Lee et al., 2004). Genes associated to protein degradation, protein
596 synthesis and transport, and various other biochemical pathways were found to be regulated. In
597 GP₅-expressing HeLa cells, actin-related protein 1 (ARP1) homologs A and B were identified to
598 be up-regulated (Lee et al., 2004). These genes encode a subunit of dynactin that binds to both
599 microtubules and cytoplasmic dynein, and is involved in ER-to-Golgi transport (Lees-Miller et
600 al., 1992). Then it is possible that the GP₅ may play a role in the intracellular transport of viral
601 and cellular components. The bisphosphoglycerate mutase (BPGM) gene was down-regulated by
602 GP₅ by more than six-folds (Lee et al., 2004). In humans, deficiency of BPGM has been shown
603 to be associated with anemia (Jacobasch, Rapoport, 1996). RASSF2 was also down-regulated by
604 GP₅. RASSF2 is a new member of the RASSF1 family and shares the properties of Ras
605 effector/tumor suppressors (Vos et al., 2003). Similarly, cyclin D3 gene expression was found to
606 be suppressed. D-type cyclins are the key regulators along with cyclin E for cell cycle
607 progression from G1 to S phase. Complexes formed between cyclin D or cyclin E and their
608 kinase partners are involved in phosphorylation of retinoblastoma protein, which ultimately leads
609 to activation of E2F transcription factor and progression to S phase of the cell cycle. Other study
610 demonstrates a clear reduction of cyclin D3 and cell cycle arrest in G0/G1 phase in cells infected
611 with mouse hepatitis coronavirus, a member of the nidoviruses (Chen, Makino, 2004). In
612 addition, a consistent increase in the expression of cathepsin genes was observed in GP₅
613 expressing cells (Lee et al., 2004). Cathepsin is involved in protein degradation. Despite the fact

614 that a specific role of cathepsin during virus replication remains to be determined, the up-
615 regulation of genes encoding proteases may represent a cellular defence against expression of
616 foreign proteins.

617 In resume, the GP₅ protein is one of the most variable proteins of PRRSV and is an
618 important virus structural protein exposed on the surface of the virion that is involved in 1) cells
619 death by apoptosis, 2) cells recognition and binding, 3) antibodies-dependent virus neutralisation
620 and 4) immune protection in immunized or infected animals. Noteworthy, GP₅ is not the only
621 determinant of a protective immunity and is particularly unlikely to be an important determinant
622 in regards to the cross protection immunity which is needed because of the broad spectrum of
623 PRRSV strains heterogeneity. The N-glycosylation of GP₅ decreases significantly the
624 immunogenicity of the nearby enclosed neutralizing epitope and provides a way to evade the
625 neutralizing antibody immune response. Other viral epitopes, which are able to induce
626 neutralizing antibodies but with a significantly lesser extent compared to GP₅, appear to reside
627 on the other PRRSV proteins like M, GP_{2a}, GP₃, and GP₄. GP₅ immunized animals develop a
628 partial protective immune response. GP₅ fusion proteins (such as M-GP₅ and GP₃-GP₅, GP₄-
629 GP₅, or GP₃-GP₄-GP₅) are able to increase the protective immune response in vaccinated
630 animals compared to GP₅ alone. Thus, it is easy to conclude that for vaccine development, GP₅
631 should be optimized in its ability to induce neutralizing antibodies by allowing its fusion with
632 other viral proteins or by reducing its N-glycosylation state. Nonetheless, all data suggest that
633 other viral proteins should be further investigated, such as the nsp proteins (see the nsp proteins
634 section bellow), if we hope to develop an efficient method to increase significantly the protection
635 of swine against PRRSV infection.

636

Minor PRRSV structural proteins

637

638 Three N-glycosylated minor envelope proteins (GP_{2a}, GP₃, and GP₄) are translated from
639 ORF2a, 3, and 4 and are found in virions as a heterotrimeric form by disulfide linkage (Figure 1
640 and 2) (Wissink et al., 2005). The ORF2b gene, which is completely embedded in ORF2a,
641 encodes another non-glycosylated minor protein named E protein (Figure 2) (Wu et al., 2001).

642 The ORF2 gene (Figure 2) encodes two minor structural proteins (GP_{2a} and E) (Snijder et
643 al., 1999). It was shown that NA PRRSV ORF2 contains a small 219 nt “ORF2b” gene and its
644 translation is initiated five nucleotides downstream of the initiation codon of the large ORF2,
645 now named “ORF2a”. Using a baculovirus expression construct, it was shown that the full-
646 length ORF2 gene expressed both GP_{2a} and E in insect cells and that ORF2b is in a better context
647 for translation and may be preferentially expressed compared to ORF2a (Wu et al., 2001).

648

649

The minor glycosylated envelope viral protein GP_{2a}

650

651 The 29 to 30 kDa GP_{2a} is a putative class I integral membrane protein with an N-terminal
652 signal sequence and a C-terminal membrane anchor domain (Meulenberg et al., 1995a). The
653 GP_{2a} of the NA and EU strains possesses (Table 1) 256 and 249 aa, respectively (Meulenberg et
654 al., 1995a). The GP_{2a} of EU and NA strains of PRRSV contain 2 distinctive hydrophobic peaks
655 and share two highly conserved putative N-linked glycosylation sites (Meng et al., 1995b;
656 Meulenberg et al., 1995a; Meulenberg et al., 1997; Morozov et al., 1995; Wissink et al., 2004).
657 The significance of the N-glycosylation of the GP_{2a} protein for virus production and viral
658 infectivity has been investigated in regards to the EU LV strain (Wissink et al., 2004). After

659 analysing the GP_{2a} protein of virus mutants, the results showed that the GP_{2a} N-linked glycans
660 are not essential for virus particle formation (Wissink et al., 2004). The antigenicity of the GP_{2a}
661 is largely unexplored and there is no data in regards to the NA strains. Two GP_{2a} linear epitopes
662 were found to be immunoreactive with 60% (9/15) of swine sera (de Lima et al., 2006). The
663 reactive peptides comprise regions at aa positions 41–55 and 121–135. Using phage-displayed
664 peptides, three weakly antigenic B-cell epitopes were identified in the GP_{2a} at positions 36–51,
665 117–139 and 120–142 (Oleksiewicz et al., 2002). When ORF2 and ORF4 genes (which encode
666 for minor structural glycoproteins GP_{2a}/E and GP₄, respectively) were individually deleted from
667 the viral genome of a NA strain, both PRRSV deletion mutants were non-viable in MARC-145
668 cells and PAM, indicating that both genes are essential for virus replication (Welch et al., 2004).

669

670 **The minor non-glycosylated envelope viral protein E**

671

672 The E protein is an unglycosylated small hydrophobic protein which is membrane-
673 associated and believed to be present in all arteriviruses (Snijder et al., 1999; Wu et al., 2001).
674 The PRRSV E protein, is translated from the internal ORF2b starting from the +6 nucleotide
675 position in mRNA2 (Figure 2) (Snijder et al., 1999). The E protein of the NA and EU strains
676 possesses (Table 1) 73 and 70 aa, respectively (Wu et al., 2001). The E protein is a small 10 kDa
677 protein with a central hydrophobic domain, and an hydrophilic C terminus containing a cluster of
678 basic residues (Snijder et al., 1999). In addition, the E protein possesses a potential N-terminal
679 N-myristoylation site and a potential casein kinase II phosphorylation site (Snijder et al., 1999).
680 The E protein of PRRSV has been identified to be incorporated into the envelope virion structure
681 such as its EAV homologous protein (Wu et al., 2005) (Figure 1).

682 Besides its structural function, the E protein function is currently unknown. Reverse
683 genetics, using an infectious EAV clone, demonstrated that the E protein is required for the
684 production of infectious virions (Snijder et al., 1999). It was shown that a covalent association of
685 the E protein with the GP_{2b}-GP₃-GP₄ heterotrimers exists in EAV, suggesting a possible role of
686 the heteromultimeric complex in the virus entry process. The absence of the E protein entirely
687 prevented the incorporation of the GP_{2b}-GP₃-GP₄ proteins into viral particles (Wieringa et al.,
688 2004). Several studies using a EU PRRSV isolate showed that the E protein is incorporated into
689 the virions and associated covalently with GP_{2a}-GP₃-GP₄ heterotrimers (Figure 1), suggesting a
690 critical role for the heteromultimeric complex (Wissink et al., 2005). The PRRSV E protein
691 possesses two cysteines at positions 49 and 54 that are highly conserved among NA isolates. The
692 importance of the cysteine residues of the E protein was determined using a NA PRRSV
693 infectious cDNA clone. Each cysteine was substituted by a serine. When the mutated PRRSV
694 infectious cDNA clone were transfected into MARC-145 cells, all cysteine mutant clones
695 induced PRRSV-specific cytopathic effects and produced infectious progeny virus. The data
696 indicates that cysteine residues in the E protein are not essential for PRRSV replication (Lee,
697 Yoo, 2005). In addition, the results obtained show that the N and E proteins of PRRSV do not
698 form cysteine-linked covalent linkages but that they do form cysteine-independent non-covalent
699 associations (Lee, Yoo, 2005). Therefore, the authors postulated that the interaction between N
700 and E may be initiated following the binding of viral RNA to the N protein (Yoo et al., 2003).
701 Subsequently, the N-RNA interaction may promote the N protein association with E, providing
702 stable assembly of the core structure in the virion. Noteworthy, the cysteines of E protein are not
703 well conserved among arteriviruses (Snijder et al., 1999). In comparison to PRRSV NA strains,
704 the EU strains contain only a single cysteine at position 51, while E proteins of LDV, EAV and

705 SHFV contain a single cysteine residue at different positions (Snijder et al., 1999). Interestingly,
706 it was found that a single NA PRRSV mutation at arginine 51 in the basic region of E is lethal
707 for PRRSV, supporting the premise that the N–E non-covalent interaction may be a requirement
708 for PRRSV replication (Lee, Yoo, 2005). On the other hand, an infectious cDNA clone was used
709 to generate an E gene-knockout PRRSV mutant, and this study report that the E protein is
710 essential for virus infectivity but dispensable for virus particle formation (Lee, Yoo, 2006). The
711 E deleted non-infectious virus particles were able to enter cells but unable to continue further
712 steps of replication (Lee, Yoo, 2006). It is therefore tempting to speculate that PRRSV may
713 contain a viral ion channel protein to promote the uncoating process in the endosome during the
714 early stage of infection. Furthermore, two ion channel blockers were shown to greatly affect
715 PRRSV replication at early stages of infection, suggesting that ion channel activity was essential
716 for virus uncoating (Lee, Yoo, 2006). In addition it was found that expression of the E protein
717 enhances membrane permeability of hygromycin B in bacterial cells. Interestingly, the
718 coronavirus E protein has been shown to modify membrane permeability (Liao et al., 2004;
719 Madan et al., 2005) as well as to form cation-selective ion channels in an artificial membrane
720 (Wilson et al., 2004). Results obtained in a previous study support the hypothesis that the
721 PRRSV E protein may function as an ion channel for virus uncoating (Lee, Yoo, 2006).

722 Recently, the E protein myristoylation was explored using the reverse genetics approach
723 (Du et al., 2010). The E protein contains the consensus 1MGxxxS6 motif for its myristoylation,
724 and in the presence of 2-hydroxymyristic acid, the virus TCID₅₀ titer decreased by 2.5 log₁₀ and
725 the level of viral RNA was reduced significantly. Thus, the E protein myristoylation is non-
726 essential for PRRSV infectivity but promotes the growth of the virus (Du et al., 2010).

The minor glycosylated envelope viral protein GP₃

727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749

The GP₃ protein is encoded by the ORF3 (Figure 2) gene and is one of the most variable PRRSV proteins, showing approximately 54 to 60% aa identity between the NA and EU genotypes (Dea et al., 2000a). The GP₃ is comprised (Table 1) of 254 and 265 aa for NA and EU isolates, respectively (Mardassi et al., 1995a; Meng et al., 1995b; Meulenberg et al., 1995a; Murtaugh et al., 1995). Several studies have reported that the most variable region of GP₃ is located at the first 35 aa, which is 29% identical among EU and NA isolates (Katz et al., 1995; Mardassi et al., 1995a; Murtaugh et al., 1995). The 45 to 50 kDa molecular weight GP₃ protein is highly glycosylated (Table 1) and possesses seven potential N-linked oligosaccharides and has a single N terminal hydrophobic domain (Meulenberg et al., 1995a). The glycosylation sites are highly conserved among NA and EU PRRSV stains (Gonin et al., 1998; Mardassi et al., 1995a; Meulenberg et al., 1995a; Wissink et al., 2004). The GP₃ protein seems to take a special position among the arterivirus glycoproteins. Since its membrane topology has not been resolved and seems to be strain dependent (Hedges et al., 1999; Mardassi et al., 1998; Wieringa et al., 2002), its virion structural nature is also controversial (Figure 1). For LDV, the GP₃ protein was reported to be a non-structural, soluble glycoprotein that is secreted from infected cells (Faaberg, Plagemann, 1997). In contrast, the GP₃ protein of EAV was clearly demonstrated to be incorporated into virions (Wieringa et al., 2002). For PRRSV, both situations have been described (de Lima et al., 2009; Gonin et al., 1998; Mardassi et al., 1998; Meulenberg et al., 1995a; van Nieuwstadt et al., 1996; Wissink et al., 2005). Thus, the GP₃ protein of the prototype EU LV strain was found to be incorporated into virions (Meulenberg et al., 1995a; van Nieuwstadt et al., 1996) and membrane-associated as heterotrimers with GP_{2a} and GP₄ (Wissink

750 et al., 2005). However, the GP₃ protein of the IAF-Klop reference strain (a typical NA isolate)
751 was found to be non-structural and secreted from PRRSV infected cells (Gonin et al., 1998;
752 Mardassi et al., 1998). This dual nature of GP₃ is a reminiscence of viral glycoproteins which
753 could be found in several other viruses such as the glycoproteins G (gG) of alphaherpesviruses
754 (Bryant et al., 2003; Murata et al., 2002) and the E^{ms} glycoprotein of bovine viral diarrhea virus
755 (BVDV) (Iqbal et al., 2004). The gG protein of alphaherpesviruses is found in the virus envelope
756 and, in some alphaherpesviruses, is also secreted after proteolytic processing. In addition, these
757 secreted forms of gG were reported to have chemokine binding activity, thereby inhibiting the
758 biological activity of these chemokines *in vitro* (Bryant et al., 2003). The BVDV E^{ms} protein, in
759 addition to being a virion protein, is also secreted from infected cells into the extracellular
760 environment. This secreted form was recently shown to block the double-stranded RNA
761 interferon-inducing signal (Iqbal et al., 2004).

762 According to several reports, GP₃ is highly antigenic (Faaberg, Plagemann, 1997; Gonin
763 et al., 1998; Hedges et al., 1999; Katz et al., 1995). Although the GP₃ antibody is present at a
764 very low level in pigs, it reportedly plays a role in clearing the viral infection (Plana Duran et al.,
765 1997b) and may be involved in viral neutralization along with the GP₅ and M proteins (Cancel-
766 Tirado et al., 2004). Using a phage display library, two epitopes spanning aa regions 60–85 and
767 243–250 of a EU GP₃ protein were identified (Oleksiewicz et al., 2002; Oleksiewicz et al.,
768 2001b). Two other GP₃ epitopes of a NA strain were found and located at aa 73–87 and 66–81
769 (Zhou et al., 2006). Further analyses revealed that the two epitopes are not conserved among all
770 NA-type isolates. After analyzing the degree of antigenic variability in a series of EU isolates
771 using monoclonal antibodies, it was determined that the C-terminus antigenicity of GP₃ varied a
772 lot among the different EU isolates (Drew et al., 1995). Two replication-defective recombinant

773 adenoviruses expressing GP₃ (rAd-GP₃) or truncated GP₃ (rAd-tGP₃, a hydrophobic region of aa
774 2–64 was deleted) were constructed and their immunogenicity was tested in mice (Jiang et al.,
775 2007). The results showed that the mice immunized with recombinant adenoviruses developed
776 PRRSV-specific neutralizing antibodies and cellular immune response, including T-cell
777 proliferation responses and cytotoxic T-cell responses, by 2 weeks post-primary immunization.
778 Moreover, the levels of immune responses of mice immunized with rAd-tGP₃ were significantly
779 higher than that of mice with rAd-GP₃.

780

781 **The minor glycosylated envelope viral protein GP₄**

782

783 The 31 to 35 kDa molecular weight GP₄ protein is a putative class I integral membrane
784 protein with an N-terminal signal sequence and a C-terminal membrane anchor (Meulenberg et
785 al., 1995a). The GP₄ protein is highly glycosylated during transport through the ER–Golgi
786 complex (van Nieuwstadt et al., 1996). Four putative N-linked glycosylation sites which are
787 conserved among the NA and EU PRRSV strains are found within the protein (Meulenberg et
788 al., 1995a; van Nieuwstadt et al., 1996; Wissink et al., 2004). The aa sequence shows that GP₄
789 contains a putative N-terminal signal sequence at positions 1–22, and an additional hydrophobic
790 sequence at positions 162–178 at the C-terminus. The GP₄ protein is a minor structural protein
791 consisting of 178 and 183 aa (Table 1) for NA and EU strains, respectively (Murtaugh et al.,
792 1995) and like GP₅, is also able to induce neutralizing antibodies with lesser extent (Meulenberg
793 et al., 1997; Weiland et al., 1999). The GP₄ protein of LV possesses neutralizing epitopes which
794 are not conserved among NA and EU strains (Meulenberg et al., 1997; Weiland et al., 1999). The
795 neutralizing domain of the GP₄ of the LV strain has been mapped to a hydrophilic exposed

796 region, adjacent to its N-terminal region (aa position 40–79) which appears to be highly variable
797 among the EU strains (Meulenberg et al., 1997; Weiland et al., 1999). Approximately 65% of
798 PRRSV-positive sera obtained from affected pig farms in the US and Canada react positively by
799 immunoblotting against the *E. coli*-expressed recombinant ORF4 protein (Gonin et al., 1999;
800 Kwang et al., 1994). However, no correlation has been demonstrated between virus
801 neutralization titers of convalescent pig sera and the presence of anti-GP₄ antibodies (Gonin et
802 al., 1999). Using Pepscan technology Lima et al. (2006) detected the B-cell linear epitope in NA
803 GP₄ (aa 51-65) and using phage display libraries Oleksiewicz et al. (2001 and 2005) detected a
804 single linear epitope in EU GP₄ (aa 59-71).

805 Transfection of PRRSV permissive cells with an ORF4 deleted infectious cDNA clone
806 revealed that the ORF4 gene is essential for virus replication (Welch et al., 2004). The
807 experiments conducted by Lee and collaborators (Lee et al., 2004) demonstrated that like GP₅,
808 the GP₄ is able to alter cellular mRNA synthesis. In cell expressing GP₄, the majority of
809 differentially expressed genes were involved in synthesis, transport, and biochemical pathways
810 (Lee et al., 2004). This observation implicates that the GP₄ protein may utilize or change host
811 cell machinery to transport viral or cellular components to the cell surface.

812

813

814 In resume, the minor structural proteins are essential for virus infectivity and they are
815 incorporated into virions as a multimeric complex. Recently they became the point of interest of
816 several PRRSV investigators. Therefore, new interesting findings in regards to the function of
817 the minor viral structural proteins should be expected. The minor structural proteins multimeric
818 complex was shown to interact with the cell receptor CD163 with or without the involvement of

819 M-GP₅ heterodimers. Thus, this latest finding could lead us to formulate new important
820 questions such as: 1) can minor structural proteins multimeric complex target the virus to a
821 certain cell type and organ?; or 2) is the multimeric complex involved in the receptor-mediated
822 endocytosis virus entry? Other questions could certainly be formulated. Nonetheless, new
823 investigations in regards to the minor structural proteins will certainly help to increase our
824 understanding of PRRSV cell pathogenesis.

825

826

827 **Viral structural proteins interactions**

828

829 While the major viral structural proteins are essential for particle formation, the minor
830 viral structural proteins are essential for virus infectivity (Wissink et al., 2005). Furthermore, the
831 minor structural proteins are incorporated into virions as a multimeric complex (Figure 1).
832 Interestingly, the absences of any of the four proteins appear to affect the incorporation of all
833 three others. Thus, no GP₃ was detected in viral particles when the expression of either GP_{2a}, or
834 E, or GP₄ was prevented, and no detectable GP₄ was incorporated in the absence of GP_{2a}, E, and
835 GP₃. Similar observations were made with EAV (Wieringa et al., 2004). From these results, three
836 main conclusions could be draw. First of all, each of the membrane viral proteins is essential for
837 the production of infectious virus. Second, the GP₅ and M protein are both crucial for particle
838 formation, consistent with a role as the fundamental building blocks of the viral envelope. Third,
839 while not required for particle assembly, the minor glycoproteins GP_{2a}, GP₃, and GP₄, and
840 probably also the minor envelope protein E, interact with each other. This interaction is likely to
841 be of critical importance for their incorporation as heteromultimeric complexes into PRRSV

842 particles and essential for rendering these particles infectious (Wissink et al., 2005).
843 Noteworthy, the contradictory report in regards to the presence or the absence of GP₃ in viral
844 particles seems to be a strain dependant phenomenon and its absence does not seem to abolish
845 the formation of infectious viruses (Wissink et al., 2005). Recently, a strong interaction was
846 found between GP₄ and GP₅ proteins, although weak interactions among the other minor
847 envelope glycoproteins and GP₅ have been detected (Das et al., 2010). Both GP_{2a} and GP₄
848 proteins were found to interact with all the other viral glycoproteins resulting in the formation of
849 multiprotein complex. In addition, it was found that the multimeric complexes of the minor
850 glycoproteins, with or without the M and GP₅ proteins, are involved in direct interaction with the
851 cell surface receptor (Das et al., 2010). It appears that the GP₄ is a critical viral envelope protein
852 that not only mediates interactions with other viral envelope glycoproteins, but also along with
853 GP_{2a}, mediates interactions with the CD163 for virus entry. More specifically, it was show that
854 only the GP_{2a} and GP₄ proteins interact with CD163. Since the minor envelope proteins are not
855 required for particle formation (Wissink et al., 2005) and there are only few large multimeric
856 glycoprotein complexes present on the virion envelope (Spilman et al., 2009), these results
857 suggest that the major function of the minor glycoprotein complex on the virion envelope is to
858 interact specifically with the cell surface receptor for virus entry (Das et al., 2010).

859 Several research groups have been involved in the study of the immune response
860 triggered by each of the major structural proteins (GP₅ and M) of PRRSV (Bastos et al., 2002;
861 Bastos et al., 2004; Jiang et al., 2006b; Pirzadeh, Dea, 1998; Plana-Duran et al., 1997a, b; Qiu et
862 al., 2005) but only few information is yet available on the characterization of the minor structural
863 proteins, such as GP₃ and GP₄. A recent study (Jiang et al., 2008) reports the tandem cloning and
864 expression of two or three proteins of PRRSV, the GP₃, GP₄, or GP₅, in replication-defective

865 human adenovirus type 5 (Ad5) vectors. Mice inoculated with the recombinant Ad5 expressing
866 the GP₃-GP₅, GP₄-GP₅, or GP₃-GP₄-GP₅ of PRRSV developed a specific immune response
867 against the viral proteins, and this response was significantly increased against GP₅ when GP₃
868 and/or GP₄ were present in the adenovirus vector compared to GP₅ alone (Jiang et al., 2008).
869 These results indicated that fusion expression GP₃ and/or GP₄ with GP₅ may be an alternative
870 strategy to design more effective vaccines.

Non-structural PRRSV proteins

871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893

RNA synthesis of the positive-stranded RNA viruses that belong to the order *Nidovirales* involves the replication of the genome-length RNA (RNA1) and the synthesis of subgenomic mRNAs (sg mRNAs). Both processes are mediated by a ‘replication/transcription complex’ (RTC) composed of virus-encoded non-structural proteins (nsp) and presumably also host factors (Gorbalenya et al., 2006). Following virus entry and release of the genome into the cytoplasm, the nidovirus life cycle starts with the expression of the large replicase gene that consists of ORF1a and ORF1b (Figure 2). The replicase-associated genes, ORF1a and ORF1b, are located on the 5’ end of the genome (representing almost 75% of the viral genome) and encode for the polyproteins pp1a and pp1ab (Figure 2). The pp1a is encoded by ORF1a, and the synthesis of pp1ab occurs through a ribosomal frame shift at the ORF1a-1b junction (Brierley, 1995; Snijder, Meulenberg, 1998). The pp1a is predicted to be cleaved at eight (Figure 2) sites to form nine nsp: nsp1 α , nsp1 β , and nsp2 to nsp8 (den Boon et al., 1995; Snijder, Meulenberg, 1998). Proteolytic cleavage of the ORF1b gene portion of the pp1ab generates (Figure 2) products nsp9 through nsp12 (van Dinten, 1996). The products derived from pp1a possess proteolytic activities (Table 1) and are responsible for processing the other nsp cleavage products; whereas nsp9 to nsp12 are involved in virus transcription and replication (Snijder, Meulenberg, 1998; van Dinten, 1996). These polyproteins are immediately translated upon virus entry and then proteolytically processed by viral encoded proteinases into intermediate precursors and at least 12 mature nsp, which appear to be responsible for forming membrane-bound replication complexes, called virus-induced double-membrane vesicles and which are sites for viral RNA synthesis (Snijder, Meulenberg, 1998). The processing of pp1a and pp1ab is believed to be mediated by accessory

894 proteinases (Figure 2), located in nsp1 and nsp2, and the main serine proteinase located in nsp4,
895 the 3C-like proteinase (3CLpro) (Ziebuhr et al., 2000). The catalytic sites of these enzymes and
896 the corresponding cleavage sites of pp1a are well conserved among arteriviruses (Ziebuhr et al.,
897 2000). Processing of pp1a in PRRSV begins with the N-terminal nsp1, which is automatically
898 cleaved by papain-like cysteine proteases (PCP α and PCP β) which are contained in nsp1 (Figure
899 2) (Kroese et al., 2008), while the PCP α domain is inactive in EAV (den Boon et al., 1995;
900 Snijder et al., 1993). Arterivirus nsp2 contains a predicted cysteine proteinase (PL2pro) in its N
901 terminus (Figure 2) that was shown to cleave the pp1a at the nsp2-nsp3 junction in EAV (Snijder
902 et al., 1995b; Snijder, 1998). The 3CLpro (Figure 2) is responsible for processing the remainder
903 of ORF1a and ORF1ab into several subunits (nsp3 to 12) (van Dinten et al., 1999; Ziebuhr et al.,
904 2000).

905 The non-structural polypeptides encoded in *Nidovirales* ORF1b regions have been
906 predicted to have essential roles (Table 1) in virus replication and gene expression (Allende et
907 al., 1999; Gorbalenya, 1989; Meulenberg et al., 1993a; Nelsen et al., 1999; van Dinten, 1996).
908 Evidence for the significant role of these proteins in arteriviruses has been derived using an
909 infectious clone of EAV (van Dinten et al., 1997; van Dinten et al., 1999; van Dinten, 2000; van
910 Marle et al., 1999). Putative RNA-dependent RNA polymerase and NTPase/RNA helicase
911 motifs are associated with nsp9 and nsp10, respectively. The nsp10 also contains a putative zinc
912 finger region, which is implicated in subgenomic mRNA synthesis and genome replication.
913 Thus, it can be assumed that the reduction of ORF1ab transcripts and nsp10 expression might
914 affect negatively expression of the other viral proteins. The nsp11 contains a region with
915 unknown function, but is conserved in all nidoviruses which suggests a crucial role for this viral

916 protein (den Boon et al., 1991; Godeny et al., 1993; Gorbalenya, 1989; Meulenberg et al., 1993a;
917 van Dinten, 1996).

918 The nsp1 is a multifunctional protein (Table 1) containing two papain-like cysteine
919 proteases and a zinc-finger motif required for sg mRNA transcription (den Boon et al., 1995;
920 Kroese et al., 2008; Oleksiewicz et al., 2004; Tijms, Snijder, 2003; Tijms et al., 2001).
921 Intracellular concentrations of nsp1 may be higher than other nsp, due to translation from
922 heteroclitite RNAs (Yuan et al., 2000; Yuan et al., 2004). Its papain-like autoprotease domain
923 releases nsp1 from the replicase polyproteins, a cleavage essential for viral RNA synthesis.
924 Several mutations in the putative N-terminal zinc finger domain of nsp1 selectively abolished
925 transcription, while replication was either not affected or even increased. Other nsp1 mutations
926 did not significantly affect either replication or transcription but still dramatically reduced the
927 production of infectious progeny. Thus, nsp1 is involved in at least three consecutive key
928 processes in the EAV life cycle: ORF1ab polyprotein processing, transcription, and virion
929 biogenesis (Tijms et al., 2007). Both N-terminal cleavage products of nsp1, the nsp1 α and the
930 nsp1 β , of the replicase polyproteins of PRRSV contain a papain-like autoprotease domain,
931 which have been named PCP α and PCP β , respectively. To assess their role in the PRRSV life
932 cycle, substitutions and deletions of the presumed catalytic cysteine and histidine residues of
933 PCP α and PCP β were made into a PRRSV infectious cDNA clone. Mutations that inactivated
934 PCP α activity completely blocked sg mRNA synthesis, but did not affect genome replication. In
935 contrast, mutants in which PCP β activity was blocked proved to be non-viable and no sign of
936 viral RNA synthesis could be detected, indicating that the correct processing of the nsp1 β /nsp2
937 cleavage site is essential for PRRSV genome replication. In conclusion, the data presented here
938 shows that a productive PRRSV life cycle depends on the correct processing of both the nsp1 α

939 /nsp1 β and nsp1 β /nsp2 junctions (Kroese et al., 2008). Cleavage sites between nsp1 α /nsp1 β and
940 nsp1 β /nsp2 were identified by protein microsequencing analysis (Chen et al., 2010). The
941 cleavage site between nsp1 α /nsp1 β is located at position 180M/181A (Figure 2) and is conserved
942 among different NA PRRSV strains (Chen et al., 2010). The cleavage site between nsp1 β /nsp2 is
943 located at position 383G/384A (Figure 2) and is well conserved among different PRRSV isolates
944 (Chen et al., 2010). The replicase polyproteins of PRRSV are predicted to be cleaved into 13 nsp
945 by the nsp4 main proteinase and three accessory proteinases residing in nsp1 α , nsp1 β and nsp2
946 (van Aken et al., 2006a; van Aken et al., 2006b; van Aken et al., 2006c; Ziebuhr et al., 2000).
947 PCP α directs the release of nsp1 α , whereas the liberation of nsp1 β depends on the activities of
948 PCP α and a second proteinase, PCP β . A third cysteine proteinase, residing in the N-terminal
949 domain of nsp2, is responsible for the cleavage of the nsp2/nsp3 site (den Boon et al., 1995;
950 Snijder et al., 1995a, b; Snijder, 1998). Viral papain-like proteinases are characterized by a
951 catalytic dyad that consists of a nucleophilic cysteine residue and a downstream histidine (Figure
952 2).

953 Among the nsp, the nsp2 multidomain is the largest PRRSV replicative protein and is
954 predicted to possess approximately 980 aa (Allende et al., 1999; Ziebuhr et al., 2000). Three
955 major domains could be discerned through the alignment of arterivirus nsp2 proteins: 1) an N-
956 terminal cysteine proteinase domain (PL2), 2) a functionally unspecified middle region, and 3) a
957 hydrophobic transmembrane (TM) region near the C terminus (Han et al., 2006; Ziebuhr et al.,
958 2000). The C-terminal end of nsp2 forms a non-covalent interaction with nsp3, which together
959 form a scaffolding complex that supports the formation of double membrane vesicles and virus
960 replication complexes (Snijder, Meulenberg, 1998; Snijder et al., 2001; Snijder et al., 1994;
961 Ziebuhr et al., 2000). The PL2 of PRRSV nsp2 (Figure 2) is predicted to act on the potential

962 substrates at the nsp2-nsp3 junction and two potential cleavage sites have been proposed:
963 981G/G and 1196G/G/G (Allende et al., 1999; Ziebuhr et al., 2000), according to the knowledge
964 obtained from nsp2 of EAV, which prefers G/G dipeptides (Snijder et al., 1995b, Snijder, 1998).
965 The function of PRRSV nsp2 in the virus life cycle is poorly understood, while EAV nsp2 has
966 been shown to be involved in the generation of double-membrane vesicles together with nsp3,
967 also functions as a co-factor with nsp4 serine protease to process the other cleavage products
968 (Snijder et al., 1994; Snijder, 1995a, b; Wassenaar et al., 1997). Although PRRSV nsp2
969 possesses potential enzymatic function, it has been shown to be highly heterogeneous and
970 variable (Table 1). It is well documented that PRRSV nsp2 accounts for the major genetic
971 differences (with GP₅ major structural protein) between NA and EU PRRSV strains, sharing less
972 than 40% similarity at the aa level (Allende et al., 1999; Nelsen et al., 1999). In addition, nsp2 is
973 also the key region for genomic differentiation between PRRSV genotypes NA and EU strains.
974 Natural mutations, insertions, or, most notably, deletions are seen in the middle region or near
975 the N-terminal region of the nsp2 protein in field strains, while the putative PL2 domain,
976 predicted TM domain, as well as the predicted cleavage sites of nsp2 remain well conserved
977 (Allende et al., 1999; Fang et al., 2004; Gao et al., 2004; Han et al., 2006; Nelsen et al., 1999;
978 Ropp et al., 2004; Shen et al., 2000).

979 Areas in nsp2 with deletions and aa hypervariability are predicted to be immunologically
980 important (Fang et al., 2007). During the past 2 years, an atypical clinical outbreak, caused by a
981 highly pathogenic PRRSV strain with a unique 30 aa deletion in its nsp2 coding region, was
982 implicated in China (Li et al., 2007; Tian et al., 2007; Zhou et al., 2008). In the field, the virus
983 was associated with high mortality/morbidity in pigs of all ages, with mortality as high as 90% in
984 some herds. The mechanism for enhanced virulence was not determined but seems to be

985 associated to nsp2 30 aa deletion (Li et al., 2007). Recently, few full-length infectious cDNA
986 clones were generated, in which the nsp2 region containing the 30 aa deletion was replaced by
987 the corresponding region of the low virulence PRRSV strain (Zhou et al., 2009). The researchers
988 concluded that the 30 aa deletion is not related to the virulence of the highly pathogenic PRRSV
989 that recently emerged in China (Zhou et al., 2009).

990 The nsp2 gene may be an ideal marker for monitoring the genetic variation and for
991 developing differential diagnostic tests. Since this region tolerates mutations, including insertions
992 and deletions, nsp2 may represent the ideal site for the development of recombinant marker
993 vaccines derived from infectious clones (Fang et al., 2004). In that regards a number of studies
994 have indicated that PRRSV nsp2 is able to tolerate aa deletion and foreign gene insertion (Fang
995 et al., 2004; Fang et al., 2006; Gao et al., 2004; Han et al., 2007; Kim et al., 2007; Ran et al.,
996 2008; Tian et al., 2007) and is then an excellent gene candidate for modifications (de Lima et al.,
997 2008; Fang et al., 2006; Kim et al., 2007).

998 PRRSV non-structural proteins play a key role in processing and maturation of the
999 repertoire of structural and nsp's of the virion, but little is known about the anti-nsp immune
1000 response. In one recent study (Johnson et al., 2007), it was hypothesized that pronounced
1001 antibody responses are generated against PRRSV nsp1 and nsp2. Accordingly, nsp1 and nsp2
1002 were cloned and expressed, and antibody responses in the sera of infected and vaccinated pigs
1003 were determined (Johnson et al., 2007). Pigs mounted significant cross-reactive antibody
1004 responses against nsp1 and nsp2 that appeared equivalent to or greater than the response to N
1005 protein. Antibody reactivity to nsp1 and N was highly dependent on refolding of denatured
1006 proteins, suggesting that the porcine antibody response is directed primarily to conformational
1007 epitopes. The proteins were recognized with sera from pigs infected with PRRSV heterogeneous

1008 strains, indicating that multiple epitopes are conserved. Antibody responses against nsp1 and
1009 nsp2 were much higher than those directed against nsp4 (Johnson et al., 2007).

1010 PRRSV has been shown to be a poor inducer of interferon (IFN) *in vitro* and *in vivo*.
1011 Recently, several nsp (nsp1, nsp2, nsp4 and nsp11) were identified to downregulate the immune
1012 response (Beura et al., 2010). They were found to possess an inhibitory effect on interferon-beta
1013 (IFN- β) promoter activation for which the strongest inhibitory effect was exhibited by nsp1
1014 followed by, nsp2, nsp11, and nsp4 (Beura et al., 2010). In addition, it was found that nsp1 α ,
1015 nsp1 β and nsp11 strongly inhibit dsRNA signaling pathways. The nsp1 β was found to inhibit
1016 both IFN regulatory factor 3 (IRF3) and NF- κ B-dependent gene induction by dsRNA and Sendai
1017 virus. Investigation of IRF3 phosphorylation status after dsRNA stimulation showed that nsp1 β
1018 inhibits IRF3 (Ser396) phosphorylation and subsequently its nuclear translocation (Beura et al.,
1019 2010). Another recent report has revealed that nsp1 α and nsp1 β dramatically inhibit IFN- β
1020 expression (Chen et al., 2010). This study indicates that nsp1 β possesses the ability to inhibit
1021 both IFN synthesis and its signaling pathway, while nsp1 α alone strongly inhibits IFN synthesis.

1022 The four predicted ORF1b non-structural polypeptides comprise a putative RNA
1023 dependent RNA polymerase (POL or nsp9), a nsp10 protein (nsp10) which contains a putative
1024 metal-binding domain (MBD) and nucleoside triphosphate binding or helicase motif (HEL), and
1025 two proteins of unknown functions (nsp11 and nsp12) (Allende et al., 2000; Allende et al., 1999;
1026 Bautista et al., 2002; den Boon et al., 1991; Godeny et al., 1993; Gorbalenya, 1989; Herold et al.,
1027 1996; Meulenberg et al., 1993a; Nelsen et al., 1999; Shen et al., 2000; Snijder, Meulenberg,
1028 1998; van Dinten et al., 1999; van Dinten, 1996; Wootton et al., 2000). PRRSV nsp10 was found
1029 to possess a thermolabile and pH-sensitive NTPase activity that was modulated by
1030 polynucleotides and was able to unwind dsRNA in a 5' to 3' polarity (Bautista et al., 2002).

1031 These results provide the first evidence of the functional properties of PRRSV helicase and
1032 further support the finding that nidovirus helicases possess properties that distinguish them from
1033 other viral helicases (Bautista et al., 2002). Based on significant homology in the catalytic
1034 domains and in predicted cleavage sites of PRRSV strains it was suggested that PRRSV
1035 polymerase may undergo similar proteolytic processing as that of EAV (Snijder, Meulenberg,
1036 1998; van Dinten et al., 1999; Wassenaar et al., 1997; Ziebuhr et al., 2000).

1037

1038 Following the first identification of PRRSV in the early 90's, most of the research was
1039 oriented toward the study of the viral structural proteins. During the last five years, an
1040 increasingly significant number of reports were oriented toward the acquisition of new
1041 knowledge in regards to the non-structural viral proteins. In accordance with these recent reports,
1042 it became evident that the nsp play a tremendous role in regards to viral pathogenesis such as the
1043 immune response down regulation. The nsp ability to inhibit the IFN indicate that they are
1044 important virulence determinants. Thus, we are now entering a new exciting PRRSV research era
1045 that will focus on a better understanding of how PRRSV take control of the host immune
1046 response to its advantage.

CONCLUSION

1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069

PRRS continues to be an economically devastating disease affecting swine industry worldwide. Herein, an overview of current knowledge on virus structural and non-structural proteins in regard to viral pathogenesis was given.

To date, little is known about the biological functions of the individual nsp of PRRSV, except that they exhibit replicase, protease and polymerase activities. With the continuing emergence of viral strains, the nsp2 replicase protein with its noted mutations, insertions, and deletions has become a vital region for monitoring the rapid viral genomic evolution and for molecular epidemiology research on PRRSV (Allende et al., 1999; Fang et al., 2004; Fang et al., 2006; Fang et al., 2007; Gao et al., 2004; Han et al., 2007; Han et al., 2006; Kim et al., 2007; Ropp et al., 2004; Yoshii et al., 2008). The PRRSV nsp anti-IFN activity is certainly involved in the paradoxical immune response observed in PRRSV infected swine and would explain the inability of the host to clear PRRSV. The capability of the PRRSV nsp to interfere with the establishment of the innate and cellular antiviral state suggests that nsp are critical virulence determinants. In a near future, we could expect that research program involving nsp immune regulation of the infected host will provide important insight into the mechanism of PRRSV pathogenesis which could lead to new and innovative approaches for the control of PRRSV. In regards to viral structural proteins, it has been demonstrated that N, M and GP₅ are essential and sufficient for particle formation, but that the minor structural proteins are also required for virus infectivity (Wieringa et al., 2003; Wieringa et al., 2004; Wissink et al., 2005). The N protein seems to be the most immunogenic viral protein and an ideal target for the serological detection of infected pigs (Dea et al., 2000b; Denac et al., 1997; Ferrin et al., 2004; Seuberlich et al.,

1070 2002). Nonetheless, some non-structural viral proteins, such as nsp2, are also highly
1071 immunogenic (Fang et al., 2004; Johnson et al., 2007; Oleksiewicz et al., 2001a, 2002;
1072 Oleksiewicz et al., 2001b). In addition, nuclear and/or nucleolar localization of N protein could
1073 have an important role in cell genes expression regulation (Hiscox, 2002, 2003, 2007; Rowland,
1074 Yoo, 2003; Uchil et al., 2006; Weidman et al., 2003).

1075 It is further evident that the current vaccines based on a single PRRSV strain and on
1076 expression of GP₅ alone, are not or only partially effective (Kimman et al., 2009). Viral epitopes
1077 that are capable of inducing neutralizing antibodies appear to reside on the M, GP_{2a}, GP₃, GP₄,
1078 and GP₅ proteins (Ansari et al., 2006; Kim, Yoon, 2008; Plagemann, 2006; Yang et al., 2000). Of
1079 these, neutralizing antibodies to GP₅ appear to be most relevant for protection since most of the
1080 neutralizing Abs found in infected animals are directed against the GP₅. Unfortunately, it is also
1081 one of the most variable proteins between viral strains. Several recent studies using expression of
1082 the fusion proteins M-GP₅ and GP₃-GP₅, GP₄-GP₅, or GP₃-GP₄-GP₅ showed that specific
1083 immune response against GP₅ was significantly increased by fusion of proteins compared to
1084 animal immunized with GP₅ alone (Jiang et al., 2006a; Jiang et al., 2008). In addition, it was
1085 found that glycosylation of GP₅ of PRRSV play an important role in escaping or minimizing
1086 virus-neutralizing antibody response by a N-glycan-shielding mechanism (Kimman et al., 2009).
1087 Therefore, the glycosylation of GP₅ diminishes the immunogenicity of the nearby enclosed
1088 neutralizing epitope, and are thus critical for the induction or evasion of a neutralizing antibody
1089 response. Taken these results together, we can conclude that for vaccine development, GP₅
1090 should be optimized in its ability to induce neutralizing antibodies by allowing its fusion with
1091 other viral proteins or by reducing its glycosylation state.

1092 The virulence of PRRSV is considered to be associated with multiple factors such as, host
1093 genetic, viral genetic, environment, concomitant infections etc., and consequently it is not easy to
1094 identify the determinant regions in the genome of PRRSV involved in the viral virulence (Wang
1095 et al., 2008). However, searching any viral genomic regions or viral genes related to PRRSV
1096 virulence is an essential step toward making a contribution to the understanding of the
1097 pathogenicity of PRRSV. In order to determine virulence associated genes in PRRSV, reverse
1098 genetic has been abundantly used (Kwon et al., 2008; Wang et al., 2008). Using this
1099 experimental approach, it was found that PRRSV virulence is multigenic and resides in both the
1100 non-structural and structural viral proteins (Kwon et al., 2008; Wang et al., 2008).

ACKNOWLEDGMENT

1101

1102

1103 The authors are grateful to Cynthia M. Guilbert for critically reviewing the manuscript. Dr C.A.

1104 Gagnon is supported financially by the National Sciences and Engineering Research Council of

1105 Canada (NSERC) discovery grants, the Fédération des producteurs de porcs du Québec (FPPQ),

1106 the Centre d'insémination porcine du Québec Inc. (CIPQ), and the Conseil pour le

1107 développement de l'agriculture du Québec (CDAQ).

REFERENCES

- 1108
1109
- 1110 Albina E, (1997). Porcine reproductive and respiratory syndrome: ten years of experience (1986-
1111 1996) with this undesirable viral infection. *Veterinary Research* **28**, 305-352.
- 1112 Allende R, Kutish, GF, Laegreid W, Lu Z, Lewis TL, Rock DL, Friesen J, Galeota JA, Doster
1113 AR, Osorio FA (2000). Mutations in the genome of porcine reproductive and respiratory
1114 syndrome virus responsible for the attenuation phenotype. *Archives of Virology* **145**,
1115 1149-1161.
- 1116 Allende R, Lewis TL, Lu Z, Rock DL, Kutish GF, Ali A, Doster AR, Osorio FA (1999). North
1117 American and European porcine reproductive and respiratory syndrome viruses differ in
1118 non-structural protein coding regions. *Journal of General Virology* **80**, 307-315.
- 1119 Andreyev VG, Wesley RD, Mengeling WL, Vorwald AC, Lager KM (1997). Genetic variation
1120 and phylogenetic relationships of 22 porcine reproductive and respiratory syndrome virus
1121 (PRRSV) field strains based on sequence analysis of open reading frame 5. *Archives of*
1122 *Virology* **142**, 993-1001.
- 1123 Ansari IH, Kwon B, Osorio FA, Pattnaik AK (2006). Influence of N-linked glycosylation of
1124 porcine reproductive and respiratory syndrome virus GP5 on virus infectivity,
1125 antigenicity, and ability to induce neutralizing antibodies. *Journal of Virology* **80**, 3994-
1126 4004.
- 1127 Arrese M, Portela A (1996). Serine 3 is critical for phosphorylation at the N-terminal end of the
1128 nucleoprotein of influenza virus A/Victoria/3/75. *Journal of Virology* **70**, 3385-3391.
- 1129 Bastos RG, Dellagostin OA, Barletta RG, Doster AR, Nelson E, Osorio FA (2002). Construction
1130 and immunogenicity of recombinant Mycobacterium bovis BCG expressing GP5 and M
1131 protein of porcine reproductive respiratory syndrome virus. *Vaccine* **21**, 21-29.
- 1132 Bastos RG, Dellagostin OA, Barletta RG, Doster AR, Nelson E, Zuckermann F, Osorio FA
1133 (2004). Immune response of pigs inoculated with Mycobacterium bovis BCG expressing
1134 a truncated form of GP5 and M protein of porcine reproductive and respiratory syndrome
1135 virus. *Vaccine* **22**, 467-474.
- 1136 Bautista EM, Faaberg KS, Mickelson D, McGruder ED (2002). Functional properties of the
1137 predicted helicase of porcine reproductive and respiratory syndrome virus. *Virology* **298**,
1138 258-270.

1139 Bautista EM, Goyal SM, Yoon IJ, Joo HS, Collins JE (1993). Comparison of porcine alveolar
1140 macrophages and CL 2621 for the detection of porcine reproductive and respiratory
1141 syndrome (PRRS) virus and anti-PRRS antibody. *Journal of Veterinary Diagnostic*
1142 *Investigation* **5**, 163-165.

1143 Benfield DA, Nelson E, Collins JE, Harris L, Goyal SM, Robison D, Christianson WT, Morrison
1144 RB, Gorcyca D, Chladek D (1992). Characterization of swine infertility and respiratory
1145 syndrome (SIRS) virus (isolate ATCC VR-2332). *Journal of Veterinary Diagnostic*
1146 *Investigation* **4**, 127-133.

1147 Beura LK, Sarkar SN, Kwon B, Subramaniam S, Jones K, Pattnaik AK, Osorio FA (2010).
1148 Porcine Reproductive and Respiratory Syndrome Virus Nonstructural Protein 1 β
1149 Modulates Host Innate Immune Response by Antagonizing IRF3 Activation. *Journal of*
1150 *Virology* **84**, 1574-1584.

1151 Beyer J, Fichtner D, Schirrmeier H, Polster U, Weiland E, Wege H (2000). Porcine reproductive
1152 and respiratory syndrome virus (PRRSV): kinetics of infection in lymphatic organs and
1153 lung. *Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public*
1154 *Health* **47**, 9-25.

1155 Bilodeau R, Dea S, Sauvageau RA, Martineau GP (1991). 'Porcine reproductive and respiratory
1156 syndrome' in Quebec [letter]. *The Veterinary Record* **129**, 102-103.

1157 Bloemraad M, de Kluijver EP, Petersen A, Burkhardt GE, Wensvoort G (1994). Porcine
1158 reproductive and respiratory syndrome: temperature and pH stability of Lelystad virus
1159 and its survival in tissue specimens from viraemic pigs. *Veterinary Microbiology* **42**, 361-
1160 371.

1161 Braakman I, van Anken E (2000). Folding of viral envelope glycoproteins in the endoplasmic
1162 reticulum. *Traffic* **1**, 533-539.

1163 Brierley I (1995). Ribosomal frameshifting viral RNAs. *Journal of General Virology* **76** (Pt 8),
1164 1885-1892.

1165 Bryant NA, Davis-Poynter N, Vanderplasschen A, Alcami A (2003). Glycoprotein G isoforms
1166 from some alphaherpesviruses function as broad-spectrum chemokine binding proteins.
1167 *The EMBO Journal* **22**, 833-846.

1168 Cafruny WA, Duman RG, Wong GH, Said S, Ward-Demo P, Rowland RR, Nelson EA (2006).
1169 Porcine reproductive and respiratory syndrome virus (PRRSV) infection spreads by cell-

1170 to-cell transfer in cultured MARC-145 cells, is dependent on an intact cytoskeleton, and
1171 is suppressed by drug-targeting of cell permissiveness to virus infection. *Virology*
1172 *Journal* **3**, 90.

1173 Calvert JG, Slade DE, Shields SL, Jolie R, Mannan RM, Ankenbauer RG, Welch SK (2007).
1174 CD163 expression confers susceptibility to porcine reproductive and respiratory
1175 syndrome viruses. *Journal of Virology* **81**, 7371-7379.

1176 Cancel-Tirado SM, Evans RB, Yoon KJ (2004). Monoclonal antibody analysis of porcine
1177 reproductive and respiratory syndrome virus epitopes associated with antibody-dependent
1178 enhancement and neutralization of virus infection. *Veterinary Immunology and*
1179 *Immunopathology* **102**, 249-262.

1180 Cavanagh D (1997). Nidovirales: a new order comprising Coronaviridae and Arteriviridae.
1181 *Archives of Virology* **142**, 629-633.

1182 Chang HW, Jeng CR, Lin CM, Liu JJ, Chang CC, Tsai YC, Chia MY, Pang VF (2007). The
1183 involvement of Fas/FasL interaction in porcine circovirus type 2 and porcine
1184 reproductive and respiratory syndrome virus co-inoculation-associated lymphocyte
1185 apoptosis in vitro. *Veterinary Microbiology*.

1186 Chang HW, Jeng CR, Liu JJ, Lin TL, Chang CC, Chia MY, Tsai YC, Pang VF (2005).
1187 Reduction of porcine reproductive and respiratory syndrome virus (PRRSV) infection in
1188 swine alveolar macrophages by porcine circovirus 2 (PCV2)-induced interferon-alpha.
1189 *Veterinary Microbiology*.

1190 Chen CJ, Makino S (2004). Murine coronavirus replication induces cell cycle arrest in G0/G1
1191 phase. *Journal of Virology* **78**, 5658-5669.

1192 Chen H, Wurm T, Britton P, Brooks G, Hiscox JA (2002). Interaction of the coronavirus
1193 nucleoprotein with nucleolar antigens and the host cell. *Journal of Virology* **76**, 5233-
1194 5250.

1195 Chen Z, Li K, Plagemann PG (2000). Neuropathogenicity and sensitivity to antibody
1196 neutralization of lactate dehydrogenase-elevating virus are determined by
1197 polylectosaminoglycan chains on the primary envelope glycoprotein. *Virology* **266**, 88-
1198 98.

1199 Chen Z, Sun LZ, Zhou X, Guan X, Christopher-Hennings J, Nelson EA, Fang Y (2010).
1200 Identification of two auto-cleavage products of nonstructural protein 1 (nsp1) in porcine

1201 reproductive and respiratory syndrome virus infected cells: nsp1 function as interferon
1202 antagonist. *Virology* **398**, 87-97.

1203 Cheon DS, Chae C, Lee YS (1997). Detection of nucleic acids of porcine reproductive and
1204 respiratory syndrome virus in the lungs of naturally infected piglets as determined by in-
1205 situ hybridization. *Journal of Comparative Pathology* **117**, 157-163.

1206 Choi C, Chae C (2002). Expression of tumour necrosis factor-alpha is associated with apoptosis
1207 in lungs of pigs experimentally infected with porcine reproductive and respiratory
1208 syndrome virus. *Research in Veterinary Science* **72**, 45-49.

1209 Christianson WT (1992). Stillbirths, mummies, abortions, and early embryonic death. *The*
1210 *Veterinary Clinics of North America. Food Animal Practice* **8**, 623-639.

1211 Collins JE, Benfield DA, Christianson WT, Harris L, Hennings JC, Shaw DP, Goyal SM,
1212 McCullough S, Morrison RB, Joo HS, et al (1992). Isolation of swine infertility and
1213 respiratory syndrome virus (isolate ATCC VR-2332) in North America and experimental
1214 reproduction of the disease in gnotobiotic pigs. *Journal of Veterinary Diagnostic*
1215 *Investigation* **4**, 117-126.

1216 Costers S, Lefebvre DJ, Delputte PL, Nauwynck HJ (2008). Porcine reproductive and respiratory
1217 syndrome virus modulates apoptosis during replication in alveolar macrophages. *Archives*
1218 *of Virology* **153**, 1453-1465.

1219 Das PB, Dinh PX, Ansari IH, de Lima M, Osorio FA, Pattnaik AK (2010). The Minor Envelope
1220 Glycoproteins GP2a and GP4 of Porcine Reproductive and Respiratory Syndrome Virus
1221 Interact with the Receptor CD163. *Journal of Virology* **84**, 1731-1740.

1222 de Haan CA, Kuo L, Masters PS, Vennema H, Rottier PJ (1998). Coronavirus particle assembly:
1223 primary structure requirements of the membrane protein. *Journal of Virology* **72**, 6838-
1224 6850.

1225 de Lima M, Ansari IH, Das PB, Ku BJ, Martinez-Lobo FJ, Pattnaik AK, Osorio FA (2009). GP3
1226 is a structural component of the PRRSV type II (US) virion. *Virology* **390**, 31-36.

1227 de Lima M, Kwon B, Ansari IH, Pattnaik AK, Flores EF, Osorio FA (2008). Development of a
1228 porcine reproductive and respiratory syndrome virus differentiable (DIVA) strain through
1229 deletion of specific immunodominant epitopes. *Vaccine* **26**, 3594-3600.

- 1230 de Lima M, Pattnaik AK, Flores EF, Osorio FA (2006). Serologic marker candidates identified
1231 among B-cell linear epitopes of Nsp2 and structural proteins of a North American strain
1232 of porcine reproductive and respiratory syndrome virus. *Virology* **353**, 410-421.
- 1233 de Vries AA, Chirnside ED, Horzinek MC, Rottier PJ (1992). Structural proteins of equine
1234 arteritis virus. *Journal of Virology* **66**, 6294-6303.
- 1235 de Vries AA, Post SM, Raamsman MJ, Horzinek MC, Rottier PJ (1995). The two major
1236 envelope proteins of equine arteritis virus associate into disulfide-linked heterodimers.
1237 *Journal of Virology* **69**, 4668-4674.
- 1238 Dea S, Bilodeau R, Athanasious R, Sauvageau RA, Martineau GP (1992). PRRS syndrome in
1239 Quebec: isolation of a virus serologically related to Lelystad virus [letter]. *The Veterinary*
1240 *Record* **130**, 167.
- 1241 Dea S, Gagnon CA, Mardassi H, Milane G (1996). Antigenic variability among North American
1242 and European strains of porcine reproductive and respiratory syndrome virus as defined
1243 by monoclonal antibodies to the matrix protein. *Journal of Clinical Microbiology* **34**,
1244 1488-1493.
- 1245 Dea S, Gagnon CA, Mardassi H, Pirzadeh B, Rogan D (2000a). Current knowledge on the
1246 structural proteins of porcine reproductive and respiratory syndrome (PRRS) virus:
1247 comparison of the North American and European isolates. *Archives of Virology* **145**, 659-
1248 688.
- 1249 Dea S, Wilson L, Therrien D, Cornaglia E (2000b). Competitive ELISA for detection of
1250 antibodies to porcine reproductive and respiratory syndrome virus using recombinant E.
1251 coli-expressed nucleocapsid protein as antigen. *Journal of Virological Methods* **87**, 109-
1252 122.
- 1253 Dee S, Otake S, Oliveira S, Deen J (2009). Evidence of long distance airborne transport of
1254 porcine reproductive and respiratory syndrome virus and *Mycoplasma hyopneumoniae*.
1255 *Veterinary Research* **40**, 39.
- 1256 Delputte PL, Nauwynck HJ (2004). Porcine arterivirus infection of alveolar macrophages is
1257 mediated by sialic acid on the virus. *Journal of Virology* **78**, 8094-8101.
- 1258 Delputte PL, Van Breedam W, Barbe F, Van Reeth K, Nauwynck HJ (2007a). IFN-alpha
1259 Treatment Enhances Porcine Arterivirus infection of Monocytes via Upregulation of the

1260 Porcine Arterivirus Receptor Sialoadhesin. *Journal of Interferon and Cytokine Research*
1261 **27**, 757-766.

1262 Delputte PL, Van Breedam W, Delrue I, Oetke C, Crocker PR, Nauwynck HJ (2007b). Porcine
1263 arterivirus attachment to the macrophage-specific receptor sialoadhesin is dependent on
1264 the sialic acid-binding activity of the N-terminal immunoglobulin domain of
1265 sialoadhesin. *Journal of Virology* **81**, 9546-9550.

1266 Delputte PL, Vanderheijden N, Nauwynck HJ, Pensaert MB (2002). Involvement of the matrix
1267 protein in attachment of porcine reproductive and respiratory syndrome virus to a
1268 heparinlike receptor on porcine alveolar macrophages. *Journal of Virology* **76**, 4312-
1269 4320.

1270 den Boon JA, Faaberg KS, Meulenberg JJ, Wassenaar AL, Plagemann PG, Gorbalenya AE,
1271 Snijder EJ (1995). Processing and evolution of the N-terminal region of the arterivirus
1272 replicase ORF1a protein: identification of two papainlike cysteine proteases. *Journal of*
1273 *Virology* **69**, 4500-4505.

1274 den Boon JA, Snijder EJ, Chirnside ED, de Vries AA, Horzinek MC, Spaan WJ (1991). Equine
1275 arteritis virus is not a togavirus but belongs to the coronaviruslike superfamily. *Journal of*
1276 *Virology* **65**, 2910-2920.

1277 Denac H, Moser C, Tratschin JD, Hofmann MA (1997). An indirect ELISA for the detection of
1278 antibodies against porcine reproductive and respiratory syndrome virus using
1279 recombinant nucleocapsid protein as antigen. *Journal of Virological Methods* **65**, 169-
1280 181.

1281 Doan DN, Dokland T (2003a). Cloning, expression, purification, crystallization and preliminary
1282 X-ray diffraction analysis of the structural domain of the nucleocapsid N protein from
1283 porcine reproductive and respiratory syndrome virus (PRRSV). *Acta Crystallographica.*
1284 *Section D, Biological Crystallography* **59**, 1504-1506.

1285 Doan DN, Dokland T (2003b). Structure of the nucleocapsid protein of porcine reproductive and
1286 respiratory syndrome virus. *Structure (Camb)* **11**, 1445-1451.

1287 Dobbe JC, van der Meer Y, Spaan WJ, Snijder EJ (2001). Construction of chimeric arteriviruses
1288 reveals that the ectodomain of the major glycoprotein is not the main determinant of
1289 equine arteritis virus tropism in cell culture. *Virology* **288**, 283-294.

- 1290 Doms RW, Lamb RA, Rose JK, Helenius A (1993). Folding and assembly of viral membrane
1291 proteins. *Virology* **193**, 545-562.
- 1292 Drew TW, Lowings JP, Yapp F (1997). Variation in open reading frames 3, 4 and 7 among
1293 porcine reproductive and respiratory syndrome virus isolates in the UK. *Veterinary*
1294 *Microbiology* **55**, 209-221.
- 1295 Drew TW, Meulenbergh JJ, Sands JJ, Paton DJ (1995). Production, characterization and reactivity
1296 of monoclonal antibodies to porcine reproductive and respiratory syndrome virus.
1297 *Journal of General Virology* **76**, 1361-1369.
- 1298 Du Y, Zuckermann FA, Yoo D (2010). Myristoylation of the small envelope protein of porcine
1299 reproductive and respiratory syndrome virus is non-essential for virus infectivity but
1300 promotes its growth. *Virus Research* **147**, 294-299.
- 1301 Duan X, Nauwynck HJ, Favoreel HW, Pensaert MB (1998). Identification of a putative receptor
1302 for porcine reproductive and respiratory syndrome virus on porcine alveolar
1303 macrophages. *Journal of Virology* **72**, 4520-4523.
- 1304 Duan X, Nauwynck HJ, Pensaert MB (1997). Effects of origin and state of differentiation and
1305 activation of monocytes/macrophages on their susceptibility to porcine reproductive and
1306 respiratory syndrome virus (PRRSV). *Archives of virology* **142**, 2483-2497.
- 1307 Faaberg KS, Even C, Palmer GA, Plagemann PG (1995a). Disulfide bonds between two
1308 envelope proteins of lactate dehydrogenase-elevating virus are essential for viral
1309 infectivity. *Journal of Virology* **69**, 613-617.
- 1310 Faaberg KS, Palmer GA, Even C, Anderson GW, Plagemann PG (1995b). Differential
1311 glycosylation of the ectodomain of the primary envelope glycoprotein of two strains of
1312 lactate dehydrogenase-elevating virus that differ in neuropathogenicity. *Virus Research*
1313 **39**, 331-340.
- 1314 Faaberg KS, Plagemann PG (1995). The envelope proteins of lactate dehydrogenase-elevating
1315 virus and their membrane topography. *Virology* **212**, 512-525.
- 1316 Faaberg KS, Plagemann PG (1997). ORF 3 of lactate dehydrogenase-elevating virus encodes a
1317 soluble, nonstructural, highly glycosylated, and antigenic protein. *Virology* **227**, 245-251.
- 1318 Fang Y, Kim DY, Ropp S, Steen P, Christopher-Hennings J, Nelson EA, Rowland RR (2004).
1319 Heterogeneity in Nsp2 of European-like porcine reproductive and respiratory syndrome
1320 viruses isolated in the United States. *Virus Research* **100**, 229-235.

- 1321 Fang Y, Rowland RR, Roof M, Lunney JK, Christopher-Hennings J, Nelson EA (2006). A full-
1322 length cDNA infectious clone of North American type 1 porcine reproductive and
1323 respiratory syndrome virus: expression of green fluorescent protein in the Nsp2 region.
1324 *Journal of Virology* **80**, 11447-11455.
- 1325 Fang Y, Schneider P, Zhang WP, Faaberg KS, Nelson EA, Rowland RR (2007). Diversity and
1326 evolution of a newly emerged North American Type 1 porcine arterivirus: analysis of
1327 isolates collected between 1999 and 2004. *Archives of Virology* **152**, 1009-1017.
- 1328 Fernandez A, Suarez P, Castro JM, Tabares E, Diaz-Guerra M (2002). Characterization of
1329 regions in the GP5 protein of porcine reproductive and respiratory syndrome virus
1330 required to induce apoptotic cell death. *Virus Research* **83**, 103-118.
- 1331 Ferrin NH, Fang Y, Johnson CR, Murtaugh MP, Polson DD, Torremorell M, Gramer ML,
1332 Nelson EA (2004). Validation of a blocking enzyme-linked immunosorbent assay for
1333 detection of antibodies against porcine reproductive and respiratory syndrome virus.
1334 *Clinical and Diagnostic Laboratory Immunology* **11**, 503-514.
- 1335 Fitter S, Sincock PM, Jolliffe CN, Ashman LK (1999). Transmembrane 4 superfamily protein
1336 CD151 (PETA-3) associates with beta 1 and alpha IIb beta 3 integrins in haemopoietic
1337 cell lines and modulates cell-cell adhesion. *The Biochemical Journal* **338** (Pt 1), 61-70.
- 1338 Forsberg R (2005). Divergence Time of Porcine Reproductive and Respiratory Syndrome Virus
1339 Sub-types. *The Molecular Biology and Evolution*.
- 1340 Forsberg R, Oleksiewicz MB, Petersen AM, Hein J, Botner A, Storgaard T (2001). A molecular
1341 clock dates the common ancestor of European-type porcine reproductive and respiratory
1342 syndrome virus at more than 10 years before the emergence of disease. *Virology* **289**,
1343 174-179.
- 1344 Forsberg R, Storgaard T, Nielsen HS, Oleksiewicz MB, Cordioli P, Sala G, Hein J, Botner A
1345 (2002). The genetic diversity of European type PRRSV is similar to that of the North
1346 American type but is geographically skewed within Europe. *Virology* **299**, 38-47.
- 1347 Gagnon CA, Dea S (1998). Differentiation between porcine reproductive and respiratory
1348 syndrome virus isolates by restriction fragment length polymorphism of their ORFs 6 and
1349 7 genes. *Canadian Journal of Veterinary Research* **62**, 110-116.
- 1350 Gagnon CA, Lachapelle G, Langelier Y, Massie B, Dea S (2003). Adenoviral-expressed GP5 of
1351 porcine respiratory and reproductive syndrome virus differs in its cellular maturation

1352 from the authentic viral protein but maintains known biological functions. *Archives of*
1353 *Virology* **148**, 951-972.

1354 Gao ZQ, Guo X, Yang HC (2004). Genomic characterization of two Chinese isolates of porcine
1355 respiratory and reproductive syndrome virus. *Archives of Virology* **149**, 1341-1351.

1356 Godeny EK, Chen L, Kumar SN, Methven SL, Koonin EV, Brinton MA (1993). Complete
1357 genomic sequence and phylogenetic analysis of the lactate dehydrogenase-elevating virus
1358 (LDV). *Virology* **194**, 585-596.

1359 Goldberg TL, Lowe JF, Milburn SM, Firkins LD (2003). Quasispecies variation of porcine
1360 reproductive and respiratory syndrome virus during natural infection. *Virology* **317**, 197-
1361 207.

1362 Gonin P, Mardassi H, Gagnon CA, Massie B, Dea S (1998). A nonstructural and antigenic
1363 glycoprotein is encoded by ORF3 of the IAF-Klop strain of porcine reproductive and
1364 respiratory syndrome virus. *Archives of Virology* **143**, 1927-1940.

1365 Gonin P, Pirzadeh B, Gagnon CA, Dea S (1999). Seroneutralization of porcine reproductive and
1366 respiratory syndrome virus correlates with antibody response to the GP5 major envelope
1367 glycoprotein. *Journal of Veterinary Diagnostic Investigation* **11**, 20-26.

1368 Gorbalenya AE, Enjuanes L, Ziebuhr J, Snijder EJ (2006). Nidovirales: evolving the largest
1369 RNA virus genome. *Virus Research* **117**, 17-37.

1370 Gorbalenya AE, Koonin EV, Donchenko AP, Blinov VM (1989). Coronavirus genome :
1371 prediction of putative functional domains in the non-structural polyprotein by
1372 comparative amino acid sequence analysis. *Nucleic Acids Research* **17**, 4847-4861.

1373 Halbur PG, Miller LD, Paul PS, Meng XJ, Huffman EL, Andrews JJ (1995).
1374 Immunohistochemical identification of porcine reproductive and respiratory syndrome
1375 virus (PRRSV) antigen in the heart and lymphoid system of three-week-old colostrum-
1376 deprived pigs. *Veterinary Pathology* **32**, 200-204.

1377 Halbur PG, Paul PS, Frey ML, Landgraf J, Eernisse K, Meng XJ, Andrews JJ, Lum MA, Rathje
1378 JA (1996a). Comparison of the antigen distribution of two US porcine reproductive and
1379 respiratory syndrome virus isolates with that of the Lelystad virus. *Veterinary Pathology*
1380 **33**, 159-170.

1381 Halbur PG, Paul PS, Meng XJ, Lum MA, Andrews JJ, Rathje JA (1996b). Comparative
1382 pathogenicity of nine US porcine reproductive and respiratory syndrome virus (PRRSV)

1383 isolates in a five-week-old cesarean-derived, colostrum-deprived pig model. *Journal of*
1384 *Veterinary Diagnostic Investigation* **8**, 11-20.

1385 Han J, Liu G, Wang Y, Faaberg KS (2007). Identification of nonessential regions of the nsp2
1386 replicase protein of porcine reproductive and respiratory syndrome virus strain VR-2332
1387 for replication in cell culture. *Journal of Virology* **81**, 9878-9890.

1388 Han J, Wang Y, Faaberg KS (2006). Complete genome analysis of RFLP 184 isolates of porcine
1389 reproductive and respiratory syndrome virus. *Virus Research* **122**, 175-182.

1390 Hanada K, Suzuki Y, Nakane T, Hirose O, Gojobori T (2005). The origin and evolution of
1391 porcine reproductive and respiratory syndrome viruses. *Molecular Biology and Evolution*
1392 **22**, 1024-1031.

1393 Hasegawa H, Nomura T, Kishimoto K, Yanagisawa K, Fujita S (1998). SFA-1/PETA-3
1394 (CD151), a member of the transmembrane 4 superfamily, associates preferentially with
1395 alpha 5 beta 1 integrin and regulates adhesion of human T cell leukemia virus type 1-
1396 infected T cells to fibronectin. *Journal of Immunology* **161**, 3087-3095.

1397 Haynes JS, Halbur PG, Sirinarumitr T, Paul PS, Meng XJ, Huffman EL (1997). Temporal and
1398 morphologic characterization of the distribution of porcine reproductive and respiratory
1399 syndrome virus (PRRSV) by in situ hybridization in pigs infected with isolates of
1400 PRRSV that differ in virulence. *Veterinary Pathology* **34**, 39-43.

1401 Hedges JF, Balasuriya UB, MacLachlan NJ (1999). The open reading frame 3 of equine arteritis
1402 virus encodes an immunogenic glycosylated, integral membrane protein. *Virology* **264**,
1403 92-98.

1404 Helenius A (1994). How N-linked oligosaccharides affect glycoprotein folding in the
1405 endoplasmic reticulum. *Molecular Biology of the Cell* **5**, 253-265.

1406 Helenius A, Aebi M (2001). Intracellular functions of N-linked glycans. *Science* **291**, 2364-2369.

1407 Helenius A, Aebi M (2004). Roles of N-linked glycans in the endoplasmic reticulum. *Annual*
1408 *Review of Biochemistry* **73**, 1019-1049.

1409 Herold J, Siddell S, Ziebuhr J (1996). Characterization of coronavirus RNA polymerase gene
1410 products. *Methods in Enzymology* **275**, 68-89.

1411 Hiscox JA (2002). The nucleolus: a gateway to viral infection? *Archives of Virology* **147**, 1077-
1412 1089.

1413 Hiscox JA (2003). The interaction of animal cytoplasmic RNA viruses with the nucleus to
1414 facilitate replication. *Virus Research* **95**, 13-22.

1415 Hiscox JA (2007). RNA viruses: hijacking the dynamic nucleolus. *Nature Reviews Microbiology*
1416 **5**, 119-127.

1417 Hiscox JA, Wurm T, Wilson L, Britton P, Cavanagh D, Brooks G (2001). The coronavirus
1418 infectious bronchitis virus nucleoprotein localizes to the nucleolus. *Journal of Virology*
1419 **75**, 506-512.

1420 Iqbal M, Poole E, Goodbourn S, McCauley JW (2004). Role for bovine viral diarrhoea virus Erns
1421 glycoprotein in the control of activation of beta interferon by double-stranded RNA.
1422 *Journal of Virology* **78**, 136-145.

1423 Jacobasch G, Rapoport SM (1996). Hemolytic anemias due to erythrocyte enzyme deficiencies.
1424 *Molecular Aspects of Medicine* **17**, 143-170.

1425 Jiang W, Jiang P, Li Y, Tang J, Wang X, Ma S (2006a). Recombinant adenovirus expressing
1426 GP5 and M fusion proteins of porcine reproductive and respiratory syndrome virus
1427 induce both humoral and cell-mediated immune responses in mice. *Veterinary*
1428 *Immunology and Immunopathology* **113**, 169-180.

1429 Jiang W, Jiang P, Li Y, Wang X, Du Y (2007). Analysis of immunogenicity of minor envelope
1430 protein GP3 of porcine reproductive and respiratory syndrome virus in mice. *Virus*
1431 *Genes*.

1432 Jiang W, Jiang P, Wang X, Li Y, Du Y (2008). Enhanced immune responses of mice inoculated
1433 recombinant adenoviruses expressing GP5 by fusion with GP3 and/or GP4 of PRRS
1434 virus. *Virus Research* **136**, 50-57.

1435 Jiang Y, Xiao S, Fang L, Yu X, Song Y, Niu C, Chen H (2006b). DNA vaccines co-expressing
1436 GP5 and M proteins of porcine reproductive and respiratory syndrome virus (PRRSV)
1437 display enhanced immunogenicity. *Vaccine* **24**, 2869-2879.

1438 Johnson CR, Yu W, Murtaugh MP (2007). Cross-reactive antibody responses to nsp1 and nsp2
1439 of Porcine reproductive and respiratory syndrome virus. *Journal of General Virology* **88**,
1440 1184-1195.

1441 Johnson WE, Lifson JD, Lang SM, Johnson RP, Desrosiers RC (2003). Importance of B-cell
1442 responses for immunological control of variant strains of simian immunodeficiency virus.
1443 *Journal of Virology* **77**, 375-381.

- 1444 Kapur V, Elam MR, Pawlovich TM, Murtaugh MP (1996). Genetic variation in porcine
1445 reproductive and respiratory syndrome virus isolates in the midwestern United States.
1446 *Journal of General Virology* **77**, 1271-1276.
- 1447 Katz JB, Shafer AL, Eernisse KA, Landgraf JG, Nelson EA (1995). Antigenic differences
1448 between European and American isolates of porcine reproductive and respiratory
1449 syndrome virus (PRRSV) are encoded by the carboxyterminal portion of viral open
1450 reading frame 3. *Veterinary Microbiology* **44**, 65-76.
- 1451 Keffaber KK (1989). Reproductive failure of unknown etiology. *American Association of Swine*
1452 *Practitioners Newsletter* **1** (2), 1-9.
- 1453 Key KF, Haqshenas G, Guenette DK, Swenson SL, Toth TE, Meng XJ (2001). Genetic variation
1454 and phylogenetic analyses of the ORF5 gene of acute porcine reproductive and
1455 respiratory syndrome virus isolates. *Veterinary Microbiology* **83**, 249-263.
- 1456 Kheyar A, Jabrane A, Zhu C, Cleroux P, Massie B, Dea S, Gagnon CA (2005). Alternative
1457 codon usage of PRRS virus ORF5 gene increases eucaryotic expression of GP(5)
1458 glycoprotein and improves immune response in challenged pigs. *Vaccine* **23**, 4016-4022.
- 1459 Kim DY, Calvert JG, Chang KO, Horlen K, Kerrigan M, Rowland RR (2007). Expression and
1460 stability of foreign tags inserted into nsp2 of porcine reproductive and respiratory
1461 syndrome virus (PRRSV). *Virus Research* **128**, 106-114.
- 1462 Kim HS, Kwang J, Yoon IJ, Joo HS, Frey ML (1993). Enhanced replication of porcine
1463 reproductive and respiratory syndrome (PRRS) virus in a homogeneous subpopulation of
1464 MA-104 cell line. *Archives of Virology* **133**, 477-483.
- 1465 Kim JK, Fahad AM, Shanmukhappa K, Kapil S (2006). Defining the cellular target(s) of porcine
1466 reproductive and respiratory syndrome virus blocking monoclonal antibody 7G10.
1467 *Journal of Virology* **80**, 689-696.
- 1468 Kim TS, Benfield DA, Rowland RR (2002). Porcine reproductive and respiratory syndrome
1469 virus-induced cell death exhibits features consistent with a nontypical form of apoptosis.
1470 *Virus Research* **85**, 133-140.
- 1471 Kim WI, Yoon KJ (2008). Molecular assessment of the role of envelope-associated structural
1472 proteins in cross neutralization among different PRRS viruses. *Virus Genes* **37**, 380-391.

- 1473 Kimman TG, Cornelissen LA, Moormann RJ, Rebel JM, Stockhofe-Zurwieden N (2009).
1474 Challenges for porcine reproductive and respiratory syndrome virus (PRRSV)
1475 vaccinology. *Vaccine* **27**, 3704-3718.
- 1476 Kiss I, Sami L, Kecskemeti S, Hanada K (2006). Genetic variation of the prevailing porcine
1477 respiratory and reproductive syndrome viruses occurring on a pig farm upon vaccination.
1478 *Archives of Virology* **151**, 2269-2276.
- 1479 Kreutz LC, Ackermann MR (1996). Porcine reproductive and respiratory syndrome virus enters
1480 cells through a low pH-dependent endocytic pathway. *Virus Research* **42**, 137-147.
- 1481 Kroese MV, Zevenhoven-Dobbe JC, Bos-de Ruijter JN, Peeters BP, Meulenberg JJ, Cornelissen
1482 LA, Snijder EJ (2008). The nsp1alpha and nsp1 papain-like autoproteases are essential
1483 for porcine reproductive and respiratory syndrome virus RNA synthesis. *Journal of*
1484 *General Virology* **89**, 494-499.
- 1485 Kwang J, Kim HS, Joo HS (1994). Cloning, expression, and sequence analysis of the ORF4 gene
1486 of the porcine reproductive and respiratory syndrome virus MN-1b. *Journal of Veterinary*
1487 *Diagnostic Investigation* **6**, 293-296.
- 1488 Kwon B, Ansari IH, Pattnaik AK, Osorio FA (2008). Identification of virulence determinants of
1489 porcine reproductive and respiratory syndrome virus through construction of chimeric
1490 clones. *Virology* **380**, 371-378.
- 1491 Labarque G, Van Gucht S, Nauwynck H, Van Reeth K, Pensaert M (2003). Apoptosis in the
1492 lungs of pigs infected with porcine reproductive and respiratory syndrome virus and
1493 associations with the production of apoptogenic cytokines. *Veterinary Research* **34**, 249-
1494 260.
- 1495 Laude H, Godet M, Bernard S, Gelfi J, Duarte M, Delmas B (1995). Functional domains in the
1496 spike protein of transmissible gastroenteritis virus. *Advances in Experimental Medicine*
1497 *and Biology* **380**, 299-304.
- 1498 Lee C, Bachand A, Murtaugh MP, Yoo D (2004). Differential host cell gene expression
1499 regulated by the porcine reproductive and respiratory syndrome virus GP4 and GP5
1500 glycoproteins. *Veterinary Immunology and Immunopathology* **102**, 189-198.
- 1501 Lee C, Calvert JG, Welch SK, Yoo D (2005). A DNA-launched reverse genetics system for
1502 porcine reproductive and respiratory syndrome virus reveals that homodimerization of the
1503 nucleocapsid protein is essential for virus infectivity. *Virology* **331**, 47-62.

1504 Lee C, Hodgins D, Calvert JG, Welch SK, Jolie R, Yoo D (2006a). Mutations within the nuclear
1505 localization signal of the porcine reproductive and respiratory syndrome virus
1506 nucleocapsid protein attenuate virus replication. *Virology* **346**, 238-250.

1507 Lee C, Hodgins DC, Calvert JG, Welch SK, Jolie R, Yoo D (2006b). The nuclear localization
1508 signal of the PRRS virus nucleocapsid protein viral replication in vitro and antibody
1509 response in vivo. *Advances in Experimental Medicine and Biology* **581**, 145-148.

1510 Lee C, Yoo D (2005). Cysteine residues of the porcine reproductive and respiratory syndrome
1511 virus small envelope protein are non-essential for virus infectivity. *Journal of General*
1512 *Virology* **86**, 3091-3096.

1513 Lee C, Yoo D (2006). The small envelope protein of porcine reproductive and respiratory
1514 syndrome virus possesses ion channel protein-like properties. *Virology* **355**, 30-43.

1515 Lee CM, Chen CH, Lu SN, Tung HD, Chou WJ, Wang JH, Chen TM, Hung CH, Huang CC,
1516 Chen WJ (2003). Prevalence and clinical implications of hepatitis B virus genotypes in
1517 southern Taiwan. *Scandinavian Journal of Gastroenterology* **38**, 95-101.

1518 Lee SM, Kleiboeker SB (2007). Porcine reproductive and respiratory syndrome virus induces
1519 apoptosis through a mitochondria-mediated pathway. *Virology* **365**, 419-434.

1520 Lees-Miller JP, Helfman DM, Schroer TA (1992). A vertebrate actin-related protein is a
1521 component of a multisubunit complex involved in microtubule-based vesicle motility.
1522 *Nature* **359**, 244-246.

1523 Li Y, Wang X, Bo K, Tang B, Yang B, Jiang W, Jiang P (2007). Emergence of a highly
1524 pathogenic porcine reproductive and respiratory syndrome virus in the Mid-Eastern
1525 region of China. *Veterinary Journal*.

1526 Liao Y, Lescar J, Tam JP, Liu DX (2004). Expression of SARS-coronavirus envelope protein in
1527 *Escherichia coli* cells alters membrane permeability. *Biochemical and Biophysical*
1528 *Research Communication* **325**, 374-380.

1529 Loemba HD, Mounir S, Mardassi H, Archambault D, Dea S (1996). Kinetics of humoral immune
1530 response to the major structural proteins of the porcine reproductive and respiratory
1531 syndrome virus. *Archives of Virology* **141**, 751-761.

1532 Lopez-Fuertes L, Campos E, Domenech N, Ezquerro A, Castro JM, Dominguez J, Alonso F
1533 (2000). Porcine reproductive and respiratory syndrome (PRRS) virus down-modulates
1534 TNF-alpha production in infected macrophages. *Virus Research* **69**, 41-46.

- 1535 Loula T (1991). Mystery pig Disease. *Agri-Practice* **12**, 23-34.
- 1536 Madan V, Garcia MdeJ, Sanz MA, Carrasco L (2005). Viroporin activity of murine hepatitis
1537 virus E protein. *FEBS Letters* **579**, 3607-3612.
- 1538 Madsen KG, Hansen CM, Madsen ES, Strandbygaard B, Botner A, Sorensen KJ (1998).
1539 Sequence analysis of porcine reproductive and respiratory syndrome virus of the
1540 American type collected from Danish swine herds. *Archives of Virology* **143**, 1683-1700.
- 1541 Magar R, Larochelle R, Robinson Y, Dubuc C (1993). Immunohistochemical detection of
1542 porcine reproductive and respiratory syndrome virus using colloidal gold. *Canadian
1543 Journal of Veterinary Research* **57**, 300-304.
- 1544 Magar R, Robinson Y, Dubuc C, Larochelle R (1995). Isolation and experimental oral
1545 transmission in pigs of a porcine reproductive and respiratory syndrome virus isolate.
1546 *Advances in Experimental Medicine and Biology* **380**, 139-144.
- 1547 Mardassi H, Gonin P, Gagnon CA, Massie B, Dea S (1998). A subset of porcine reproductive
1548 and respiratory syndrome virus GP3 glycoprotein is released into the culture medium of
1549 cells as a non-virion-associated and membrane-free (soluble) form. *Journal of Virology*
1550 **72**, 6298-6306.
- 1551 Mardassi H, Massie B, Dea S (1996). Intracellular synthesis, processing, and transport of
1552 proteins encoded by ORFs 5 to 7 of porcine reproductive and respiratory syndrome virus.
1553 *Virology* **221**, 98-112.
- 1554 Mardassi H, Mounir S, Dea S (1994a). Identification of major differences in the nucleocapsid
1555 protein genes of a Quebec strain and European strains of porcine reproductive and
1556 respiratory syndrome virus. *Journal of General Virology* **75**, 681-685.
- 1557 Mardassi H, Mounir S, Dea S (1995a). Molecular analysis of the ORFs 3 to 7 of porcine
1558 reproductive and respiratory syndrome virus, Quebec reference strain. *Archives of
1559 Virology* **140**, 1405-1418.
- 1560 Mardassi H, Mounir S, Dea S (1995b). Structural gene analysis of a Quebec reference strain or
1561 porcine reproductive and respiratory syndrome virus (PRRSV). *Advances in
1562 Experimental Medicine and Biology* **380**, 277-281.
- 1563 Mardassi H, Wilson L, Mounir S, Dea S (1994b). Detection of porcine reproductive and
1564 respiratory syndrome virus and efficient differentiation between Canadian and European

1565 strains by reverse transcription and PCR amplification. *Journal of Clinical Microbiology*
1566 32, 2197-2203.

1567 Maroto B, Ramirez JC, Almendral JM (2000). Phosphorylation status of the parvovirus minute
1568 virus of mice particle: mapping and biological relevance of the major phosphorylation
1569 sites. *Journal of Virology* **74**, 10892-10902.

1570 Mateu E, Diaz I, Darwich L, Casal J, Martin M, Pujols J (2006). Evolution of ORF5 of Spanish
1571 porcine reproductive and respiratory syndrome virus strains from 1991 to 2005. *Virus*
1572 *Research* **115**, 198-206.

1573 McNabb DS, Courtney RJ (1992). Posttranslational modification and subcellular localization of
1574 the p12 capsid protein of herpes simplex virus type 1. *Journal of Virology* **66**, 4839-4847.

1575 Meng XJ (2000). Heterogeneity of porcine reproductive and respiratory syndrome virus:
1576 implications for current vaccine efficacy and future vaccine development. *Veterinary*
1577 *Microbiology* **74**, 309-329.

1578 Meng XJ, Paul PS, Halbur PG, Lum MA (1995a). Phylogenetic analyses of the putative M (ORF
1579 6) and N (ORF 7) genes of porcine reproductive and respiratory syndrome virus
1580 (PRRSV): implication for the existence of two genotypes of PRRSV in the U.S.A. and
1581 Europe. *Archives of Virology* **140**, 745-755.

1582 Meng XJ, Paul PS, Halbur PG, Morozov I (1995b). Sequence comparison of open reading
1583 frames 2 to 5 of low and high virulence United States isolates of porcine reproductive and
1584 respiratory syndrome virus. *Journal of General Virology* **76**, 3181-3188.

1585 Meulenbergh JJ (2000). PRRSV, the virus. *Veterinary Research* **31**, 11-21.

1586 Meulenbergh JJ, de Meijer EJ, Moormann RJ (1993a). Subgenomic RNAs of Lelystad virus
1587 contain a conserved leader-body junction sequence. *Journal of General Virology* **74**,
1588 1697-1701.

1589 Meulenbergh JJ, Hulst MM, de Meijer EJ, Moonen PL, den Besten A, de Kluyver EP, Wensvoort
1590 G, Moormann RJ (1993b). Lelystad virus, the causative agent of porcine epidemic
1591 abortion and respiratory syndrome (PEARS), is related to LDV and EAV. *Virology* **192**,
1592 62-72.

1593 Meulenbergh JJ, Petersen-den Besten A, De Kluyver EP, Moormann RJ, Schaaper WM,
1594 Wensvoort G (1995a). Characterization of proteins encoded by ORFs 2 to 7 of Lelystad
1595 virus. *Virology* **206**, 155-163.

1596 Meulenberg JJ, Petersen-den Besten A, de Kluyver EP, Moormann RJ, Schaaper WM,
1597 Wensvoort G (1995b). Characterization of structural proteins of Lelystad virus. *Advances*
1598 *in Experimental Medecine and Biology* **380**, 271-276.

1599 Meulenberg JJ, Petersen den Besten A, de Kluyver E, van Nieuwstadt A, Wensvoort G,
1600 Moormann RJ (1997). Molecular characterization of Lelystad virus. *Veterinary*
1601 *Microbiology* **55**, 197-202.

1602 Meulenberg JJ, van Nieuwstadt AP, van Essen-Zandbergen A, Bos-de Ruijter JN, Langeveld JP,
1603 Meloen RH (1998). Localization and fine mapping of antigenic sites on the nucleocapsid
1604 protein N of porcine reproductive and respiratory syndrome virus with monoclonal
1605 antibodies. *Virology* **252**, 106-114.

1606 Miller LC, Fox JM (2004). Apoptosis and porcine reproductive and respiratory syndrome virus.
1607 *Veterinary Immunology and Immunopathology* **102**, 131-142.

1608 Morozov I, Meng XJ, Paul PS (1995). Sequence analysis of open reading frames (ORFs) 2 to 4
1609 of a U.S. isolate of porcine reproductive and respiratory syndrome virus. *Archives of*
1610 *Virology* **140**, 1313-1319.

1611 Murata T, Goshima F, Takakuwa H, Nishiyama Y (2002). Excretion of herpes simplex virus type
1612 2 glycoprotein D into the culture medium. *Journal of General Virology* **83**, 2791-2795.

1613 Murtaugh MP, Elam MR, Kakach LT (1995). Comparison of the structural protein coding
1614 sequences of the VR-2332 and Lelystad virus strains of the PRRS virus. *Archives of*
1615 *Virology* **140**, 1451-1460.

1616 Nelsen CJ, Murtaugh MP, Faaberg KS (1999). Porcine reproductive and respiratory syndrome
1617 virus comparison: divergent evolution on two continents. *Journal of Virology* **73**, 270-
1618 280.

1619 Nelson EA, Christopher-Hennings J, Drew T, Wensvoort G, Collins JE, Benfield DA (1993).
1620 Differentiation of U.S. and European isolates of porcine reproductive and respiratory
1621 syndrome virus by monoclonal antibodies. *Journal of Clinical Microbiology* **31**, 3184-
1622 3189.

1623 Neumann EJ, Kliebenstein JB, Johnson CD, Mabry JW, Bush EJ, Seitzinger AH, Green AL,
1624 Zimmerman JJ (2005). Assessment of the economic impact of porcine reproductive and
1625 respiratory syndrome on swine production in the United States. *Journal of the American*
1626 *Veterinary Medical Association* **227**, 385-392.

1627 Nielsen HS, Storgaard T, Oleksiewicz MB (2000). Analysis of ORF 1 in european porcine
1628 reproductive and respiratory syndrome virus by long RT-PCR and restriction fragment
1629 length polymorphism (RFLP) analysis. *Veterinary Microbiology* **76**, 221-228.

1630 Oleksiewicz MB, Botner A, Normann P (2001a). Semen from boars infected with porcine
1631 reproductive and respiratory syndrome virus (PRRSV) contains antibodies against
1632 structural as well as nonstructural viral proteins. *Veterinary Microbiology* **81**, 109-125.

1633 Oleksiewicz MB, Botner A, Normann P (2002). Porcine B-cells recognize epitopes that are
1634 conserved between the structural proteins of American- and European-type porcine
1635 reproductive and respiratory syndrome virus. *Journal of General Virology* **83**, 1407-
1636 1418.

1637 Oleksiewicz MB, Botner A, Toft P, Grubbe T, Nielsen J, Kamstrup S, Storgaard T (2000).
1638 Emergence of porcine reproductive and respiratory syndrome virus deletion mutants:
1639 correlation with the porcine antibody response to a hypervariable site in the ORF 3
1640 structural glycoprotein. *Virology* **267**, 135-140.

1641 Oleksiewicz MB, Botner A, Toft P, Normann P, Storgaard T (2001b). Epitope mapping porcine
1642 reproductive and respiratory syndrome virus by phage display: the nsp2 fragment of the
1643 replicase polyprotein contains a cluster of B-cell epitopes. *Journal of Virology* **75**, 3277-
1644 3290.

1645 Oleksiewicz MB, Snijder EJ, Normann P (2004). Phage display of the Equine arteritis virus nsp1
1646 ZF domain and examination of its metal interactions. *Journal of Virological Methods*
1647 **119**, 159-169.

1648 Osorio FA, Galeota JA, Nelson E, Brodersen B, Doster A, Wills R, Zuckermann F, Laegreid
1649 WW (2002). Passive transfer of virus-specific antibodies confers protection against
1650 reproductive failure induced by a virulent strain of porcine reproductive and respiratory
1651 syndrome virus and establishes sterilizing immunity. *Virology* **302**, 9-20.

1652 Ostrowski M, Galeota JA, Jar AM, Platt KB, Osorio FA, Lopez OJ (2002). Identification of
1653 neutralizing and nonneutralizing epitopes in the porcine reproductive and respiratory
1654 syndrome virus GP5 ectodomain. *Journal of Virology* **76**, 4241-4250.

1655 Patton JB, Rowland RR, Yoo D, Chang KO (2009). Modulation of CD163 receptor expression
1656 and replication of porcine reproductive and respiratory syndrome virus in porcine
1657 macrophages. *Virus Research* **140**, 161-171.

- 1658 Pei Y, Hodgins DC, Lee C, Calvert JG, Welch SK, Jolie R, Keith M, Yoo D (2008). Functional
1659 mapping of the porcine reproductive and respiratory syndrome virus capsid protein
1660 nuclear localization signal and its pathogenic association. *Virus Research* **135**, 107-114.
- 1661 Pirzadeh B, Dea S (1997). Monoclonal antibodies to the ORF5 product of porcine reproductive
1662 and respiratory syndrome virus define linear neutralizing determinants. *Journal of*
1663 *General Virology* **78**, 1867-1873.
- 1664 Pirzadeh B, Dea S (1998). Immune response in pigs vaccinated with plasmid DNA encoding
1665 ORF5 of porcine reproductive and respiratory syndrome virus. *Journal of General*
1666 *Virology* **79**, 989-999.
- 1667 Pirzadeh B, Gagnon CA, Dea S (1998). Genomic and antigenic variations of porcine
1668 reproductive and respiratory syndrome virus major envelope GP5 glycoprotein. *Canadian*
1669 *Journal of Veterinary Research* **62**, 170-177.
- 1670 Plagemann PG (2003). Porcine reproductive and respiratory syndrome virus: origin hypothesis.
1671 *Emerging infectious Diseases* **9**, 903-908.
- 1672 Plagemann PG (2004). GP5 ectodomain epitope of porcine reproductive and respiratory
1673 syndrome virus, strain Lelystad virus. *Virus Research* **102**, 225-230.
- 1674 Plagemann PG (2006). Neutralizing antibody formation in swine infected with seven strains of
1675 porcine reproductive and respiratory syndrome virus as measured by indirect ELISA with
1676 peptides containing the GP5 neutralization epitope. *Viral Immunology* **19**, 285-293.
- 1677 Plagemann PG, Rowland RR, Faaberg KS (2002). The primary neutralization epitope of porcine
1678 respiratory and reproductive syndrome virus strain VR-2332 is located in the middle of
1679 the GP5 ectodomain. *Archives of Virology* **147**, 2327-2347.
- 1680 Plagemann PGW (1996). Lactate dehydrogenase elevating virus and related viruses, In: Fields,
1681 B.N, Knipe DM, Howley PM (Ed.) *Field's Virology*. Lippincott-Raven, Philadelphia, pp.
1682 1105-1120.
- 1683 Plana-Duran J, Bastons M, Urniza A, Vayreda M, Vila X, Mane H (1997a). Efficacy of an
1684 inactivated vaccine for prevention of reproductive failure induced by porcine
1685 reproductive and respiratory syndrome virus. *Veterinary Microbiology* **55**, 361-370.
- 1686 Plana Duran J, Climent I, Sarraseca J, Urniza A, Cortes E, Vela C, Casal JI (1997b). Baculovirus
1687 expression of proteins of porcine reproductive and respiratory syndrome virus strain
1688 Olot/91. Involvement of ORF3 and ORF5 proteins in protection. *Virus Genes* **14**, 19-29.

1689 Pol JM, van Dijk JE, Wensvoort G, Terpstra C (1991). Pathological, ultrastructural, and
1690 immunohistochemical changes caused by Lelystad virus in experimentally induced
1691 infections of mystery swine disease (synonym: porcine epidemic abortion and respiratory
1692 syndrome (PEARS)). *The Veterinary Quarterly* **13**, 137-143.

1693 Qiu HJ, Tian ZJ, Tong GZ, Zhou YJ, Ni JQ, Luo YZ, Cai XH (2005). Protective immunity
1694 induced by a recombinant pseudorabies virus expressing the GP5 of porcine reproductive
1695 and respiratory syndrome virus in piglets. *Veterinary Immunology and Immunopathology*
1696 **106**, 309-319.

1697 Ran ZG, Chen XY, Guo X, Ge XN, Yoon KJ, Yang HC (2008). Recovery of viable porcine
1698 reproductive and respiratory syndrome virus from an infectious clone containing a partial
1699 deletion within the Nsp2-encoding region. *Archives of Virology* **153**, 899-907.

1700 Reitter JN, Desrosiers RC (1998). Identification of replication-competent strains of simian
1701 immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in
1702 variable regions 1 and 2 of the surface envelope protein. *Journal of Virology* **72**, 5399-
1703 5407.

1704 Rodriguez MJ, Sarraseca J, Garcia J, Sanz A, Plana-Duran J, Ignacio Casal J (1997). Epitope
1705 mapping of the nucleocapsid protein of European and North American isolates of porcine
1706 reproductive and respiratory syndrome virus. *Journal of General Virology* **78**, 2269-
1707 2278.

1708 Roossinck MJ, Siddiqui A (1987). In vivo phosphorylation and protein analysis of hepatitis B
1709 virus core antigen. *Journal of Virology* **61**, 955-961.

1710 Ropp SL, Wees CE, Fang Y, Nelson EA, Rossow KD, Bien M, Arndt B, Preszler S, Steen P,
1711 Christopher-Hennings J, Collins JE, Benfield DA, Faaberg KS (2004). Characterization
1712 of emerging European-like porcine reproductive and respiratory syndrome virus isolates
1713 in the United States. *Journal of Virology* **78**, 3684-3703.

1714 Rossow KD, Benfield DA, Goyal SM, Nelson EA, Christopher-Hennings J, Collins JE (1996).
1715 Chronological immunohistochemical detection and localization of porcine reproductive
1716 and respiratory syndrome virus in gnotobiotic pigs. *Veterinary Pathology* **33**, 551-556.

1717 Rossow KD, Morrison RB, Goyal SM, Singh GS, Collins JE (1994). Lymph node lesions in
1718 neonatal pigs congenitally exposed to porcine reproductive and respiratory syndrome
1719 virus. *Journal of Veterinary Diagnostic Investigation* **6**, 368-371.

1720 Rowland RR, Kervin R, Kuckleburg C, Sperlich A, Benfield DA (1999). The localization of
1721 porcine reproductive and respiratory syndrome virus nucleocapsid protein to the
1722 nucleolus of infected cells and identification of a potential nucleolar localization signal
1723 sequence. *Virus Research* **64**, 1-12.

1724 Rowland RR, Schneider P, Fang Y, Wootton S, Yoo D, Benfield DA (2003). Peptide domains
1725 involved in the localization of the porcine reproductive and respiratory syndrome virus
1726 nucleocapsid protein to the nucleolus. *Virology* **316**, 135-145.

1727 Rowland RR, Yoo D (2003). Nucleolar-cytoplasmic shuttling of PRRSV nucleocapsid protein: a
1728 simple case of molecular mimicry or the complex regulation by nuclear import, nucleolar
1729 localization and nuclear export signal sequences. *Virus Research* **95**, 23-33.

1730 Seuberlich T, Tratschin JD, Thur B, Hofmann MA (2002). Nucleocapsid protein-based enzyme-
1731 linked immunosorbent assay for detection and differentiation of antibodies against
1732 European and North American porcine reproductive and respiratory syndrome virus.
1733 *Clinical and Diagnostic Laboratory Immunology* **9**, 1183-1191.

1734 Shanmukhappa K, Kim JK, Kapil S (2007). Role of CD151, A tetraspanin, in porcine
1735 reproductive and respiratory syndrome virus infection. *Virology Journal* **4**, 62.

1736 Shen S, Kwang J, Liu W, Liu DX (2000). Determination of the complete nucleotide sequence of
1737 a vaccine strain of porcine reproductive and respiratory syndrome virus and identification
1738 of the Nsp2 gene with a unique insertion. *Archives of Virology* **145**, 871-883.

1739 Sincock PM, Fitter S, Parton RG, Berndt MC, Gamble JR, Ashman LK (1999). PETA-3/CD151,
1740 a member of the transmembrane 4 superfamily, is localised to the plasma membrane and
1741 endocytic system of endothelial cells, associates with multiple integrins and modulates
1742 cell function. *Journal of Cell Science* **112** (Pt 6), 833-844.

1743 Sirinarumitr T, Zhang Y, Kluge JP, Halbur PG, Paul PS (1998). A pneumo-virulent United
1744 States isolate of porcine reproductive and respiratory syndrome virus induces apoptosis in
1745 bystander cells both in vitro and in vivo. *Journal of General Virology* **79**, 2989-2995.

1746 Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M, Wilson IA, Wiley DC (1984). A
1747 carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits
1748 recognition by a monoclonal antibody. *Proceedings of the National Academy of Sciences
1749 of the United States of America* **81**, 1779-1783.

1750 Snijder E, Wassenaar AL, Den Boon JA, Spaan WJ (1995a). Proteolytic processing of the
1751 arterivirus replicase. *Advances in Experimental Medicine and Biology* **380**, 443-451.

1752 Snijder EJ (1998). The arterivirus replicase. The road from RNA to protein(s), and back again.
1753 *Advances in Experimental Medicine and Biology* **440**, 97-108.

1754 Snijder EJ, Dobbe JC, Spaan WJ (2003). Heterodimerization of the two major envelope proteins
1755 is essential for arterivirus infectivity. *Journal of Virology* **77**, 97-104.

1756 Snijder EJ, Meulenberg JJ (1998). The molecular biology of arteriviruses. *Journal of General*
1757 *Virology* **79**, 961-979.

1758 Snijder EJ, van Tol H, Pedersen KW, Raamsman MJ, de Vries AA (1999). Identification of a
1759 novel structural protein of arteriviruses. *Journal of Virology* **73**, 6335-6345.

1760 Snijder EJ, van Tol H, Roos N, Pedersen KW (2001). Non-structural proteins 2 and 3 interact to
1761 modify host cell membranes during the formation of the arterivirus replication complex.
1762 *Journal of General Virology* **82**, 985-994.

1763 Snijder EJ, Wassenaar AL, Spaan WJ (1993). Proteolytic processing of the N-terminal region of
1764 the equine arteritis virus replicase. *Advances in Experimental Medicine and Biology* **342**,
1765 227-232.

1766 Snijder EJ, Wassenaar AL, Spaan WJ (1994). Proteolytic processing of the replicase ORF1a
1767 protein of equine arteritis virus. *Journal of Virology* **68**, 5755-5764.

1768 Snijder EJ, Wassenaar ALM, Spaan WJM, Gorbalenya AE (1995b). The arterivirus nsp2
1769 protease: an unusual cysteine protease with primary structure similarities to both papain-
1770 like and chymotrypsin-like proteases. *Journal of Biological Chemistry* **270**, 16671-16676.

1771 Song C, Lu R, Bienzle D, Liu HC, Yoo D (2009). Interaction of the porcine reproductive and
1772 respiratory syndrome virus nucleocapsid protein with the inhibitor of MyoD family-a
1773 domain-containing protein. *Biological Chemistry* **390**, 215-223.

1774 Spilman MS, Welbon C, Nelson E, Dokland T (2009). Cryo-electron tomography of porcine
1775 reproductive and respiratory syndrome virus: organization of the nucleocapsid. *Journal of*
1776 *General Virology* **90**, 527-535.

1777 Stadejek T, Stankevicius A, Storgaard T, Oleksiewicz MB, Belak S, Drew TW, Pejsak Z (2002).
1778 Identification of radically different variants of porcine reproductive and respiratory
1779 syndrome virus in Eastern Europe: towards a common ancestor for European and
1780 American viruses. *Journal of General Virology* **83**, 1861-1873.

- 1781 Suarez P, Diaz-Guerra M, Prieto C, Esteban M, Castro JM, Nieto A, Ortin J (1996a). Open
1782 reading frame 5 of porcine reproductive and respiratory syndrome virus as a cause of
1783 virus-induced apoptosis. *Journal of Virology* **70**, 2876-2882.
- 1784 Suarez P, Zardoya R, Martin MJ, Prieto C, Dopazo J, Solana A, Castro JM (1996b).
1785 Phylogenetic relationships of european strains of porcine reproductive and respiratory
1786 syndrome virus (PRRSV) inferred from DNA sequences of putative ORF-5 and ORF-7
1787 genes. *Virus Research* **42**, 159-165.
- 1788 Sur JH, Cooper VL, Galeota JA, Hesse RA, Doster AR, Osorio FA (1996). In vivo detection of
1789 porcine reproductive and respiratory syndrome virus RNA by in situ hybridization at
1790 different times postinfection. *Journal of Clinical Microbiology* **34**, 2280-2286.
- 1791 Sur JH, Doster AR, Christian JS, Galeota JA, Wills RW, Zimmerman JJ, Osorio FA (1997).
1792 Porcine reproductive and respiratory syndrome virus replicates in testicular germ cells,
1793 alters spermatogenesis, and induces germ cell death by apoptosis. *Journal of Virology* **71**,
1794 9170-9179.
- 1795 Sur JH, Doster AR, Osorio FA (1998). Apoptosis induced in vivo during acute infection by
1796 porcine reproductive and respiratory syndrome virus. *Veterinary Pathology* **35**, 506-514.
- 1797 Teifke JP, Dauber M, Fichtner D, Lenk M, Polster U, Weiland E, Beyer J (2001). Detection of
1798 European porcine reproductive and respiratory syndrome virus in porcine alveolar
1799 macrophages by two-colour immunofluorescence and in-situ hybridization-
1800 immunohistochemistry double labelling. *Journal of Comparative Pathology* **124**, 238-
1801 245.
- 1802 Tian K, Yu X, Zhao T, Feng Y, Cao Z, Wang C, Hu Y, Chen X, Hu D, Tian X, Liu D, Zhang S,
1803 Deng X, Ding Y, Yang L, Zhang Y, Xiao H, Qiao M, Wang B, Hou L, Wang X, Yang X,
1804 Kang L, Sun M, Jin P, Wang S, Kitamura Y, Yan J, Gao GF (2007). Emergence of fatal
1805 PRRSV variants: unparalleled outbreaks of atypical PRRS in China and molecular
1806 dissection of the unique hallmark. *PLoS ONE* **2**, e526.
- 1807 Tijms MA, Nedialkova DD, Zevenhoven-Dobbe JC, Gorbalenya AE, Snijder EJ (2007).
1808 Arterivirus subgenomic mRNA synthesis and virion biogenesis depend on the
1809 multifunctional ns1 autoprotease. *Journal of Virology* **81**, 10496-10505.

1810 Tijms MA, Snijder EJ (2003). Equine arteritis virus non-structural protein 1, an essential factor
1811 for viral subgenomic mRNA synthesis, interacts with the cellular transcription co-factor
1812 p100. *Journal of General Virology* **84**, 2317-2322.

1813 Tijms MA, van der Meer Y, Snijder EJ (2002). Nuclear localization of non-structural protein 1
1814 and nucleocapsid protein of equine arteritis virus. *Journal of General Virology* **83**, 795-
1815 800.

1816 Tijms MA, van Dinten LC, Gorbalenya AE, Snijder EJ (2001). A zinc finger-containing papain-
1817 like protease couples subgenomic mRNA synthesis to genome translation in a positive-
1818 stranded RNA virus. *Proceedings of the National Academy of Sciences of the United*
1819 *States of America* **98**, 1889-1894.

1820 Uchil PD, Kumar AV, Satchidanandam V (2006). Nuclear localization of flavivirus RNA
1821 synthesis in infected cells. *Journal of Virology* **80**, 5451-5464.

1822 van Aken D, Benckhuijsen WE, Drijfhout JW, Wassenaar AL, Gorbalenya AE, Snijder EJ
1823 (2006a). Expression, purification, and in vitro activity of an arterivirus main proteinase.
1824 *Virus Research* **120**, 97-106.

1825 van Aken D, Snijder EJ, Gorbalenya AE (2006b). Mutagenesis analysis of the nsp4 main
1826 proteinase reveals determinants of arterivirus replicase polyprotein autoprocessing.
1827 *Journal of Virology* **80**, 3428-3437.

1828 van Aken D, Zevenhoven-Dobbe J, Gorbalenya AE, Snijder EJ (2006c). Proteolytic maturation
1829 of replicase polyprotein pp1a by the nsp4 main proteinase is essential for equine arteritis
1830 virus replication and includes internal cleavage of nsp7. *Journal of General Virology* **87**,
1831 3473-3482.

1832 van Dinten LC, den Boon JA, Wassenaar AL, Spaan WJ, Snijder EJ (1997). An infectious
1833 arterivirus cDNA clone: identification of a replicase point mutation that abolishes
1834 discontinuous mRNA transcription. *Proceedings of the National Academy of Sciences of*
1835 *the United States of America* **94**, 991-996.

1836 van Dinten LC, Rensen S, Gorbalenya AE, Snijder EJ (1999). Proteolytic processing of the open
1837 reading frame 1b-encoded part of arterivirus replicase is mediated by nsp4 serine protease
1838 and is essential for virus replication. *Journal of Virology* **73**, 2027-2037.

1839 van Dinten LC, Van Tol H, Gorbalenya AE, Snijder EJ (2000). The predicted metal-binding
1840 region of the arterivirus helicase protein is involved in subgenomic mRNA synthesis,
1841 genome replication and virion biogenesis. *Journal of Virology* **74**, 5213-5223.

1842 van Dinten LC, Wassenaar ALM, Gorbalenya AE, Spaan WJM, Snijder EJ (1996). Processing of
1843 the equine arteritis virus replicase ORF1b protein : identification of cleavage products
1844 containing the putative viral polymerase and helicase domains. *Journal of Virology* **70**,
1845 6625-6633.

1846 van Gorp H, Van Breedam W, Delputte PL, Nauwynck HJ (2008). Sialoadhesin and CD163 join
1847 forces during entry of the porcine reproductive and respiratory syndrome virus. *Journal*
1848 *of General Virology* **89**, 2943-2953.

1849 van Marle G, van Dinten LC, Spaan WJ, Luytjes W, Snijder EJ (1999). Characterization of an
1850 equine arteritis virus replicase mutant defective in subgenomic mRNA synthesis. *Journal*
1851 *of Virology* **73**, 5274-5281.

1852 van Nieuwstadt AP, Meulenber JJ, van Essen-Zanbergen A, Petersen-den Besten A, Bende, RJ,
1853 Moormann RJ, Wensvoort G (1996). Proteins encoded by open reading frames 3 and 4 of
1854 the genome of Lelystad virus (Arteriviridae) are structural proteins of the virion. *Journal*
1855 *of Virology* **70**, 4767-4772.

1856 Vennema H, Godeke GJ, Rossen JW, Voorhout WF, Horzinek MC, Opstelten DJ, Rottier PJ
1857 (1996). Nucleocapsid-independent assembly of coronavirus-like particles by co-
1858 expression of viral envelope protein genes. *The EMBO Journal* **15**, 2020-2028.

1859 Verheije MH, Welting TJ, Jansen HT, Rottier PJ, Meulenber JJ (2002). Chimeric arteriviruses
1860 generated by swapping of the M protein ectodomain rule out a role of this domain in viral
1861 targeting. *Virology* **303**, 364-373.

1862 Voicu IL, Silim A, Morin M, Elazhary MA (1994). Interaction of porcine reproductive and
1863 respiratory syndrome virus with swine monocytes. *The Veterinary Record* **134**, 422-423.

1864 Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ (2003). RASSF2 is a novel K-Ras-
1865 specific effector and potential tumor suppressor. *The Journal of Biological Chemistry*
1866 **278**, 28045-28051.

1867 Wang Y, Liang Y, Han J, Burkhart KM, Vaughn EM, Roof MB, Faaberg KS (2008). Attenuation
1868 of porcine reproductive and respiratory syndrome virus strain MN184 using chimeric
1869 construction with vaccine sequence. *Virology* **371**, 418-429.

1870 Wassenaar AL, Spaan WJ, Gorbalenya AE, Snijder EJ (1997). Alternative proteolytic processing
1871 of the arterivirus replicase ORF1a polyprotein: evidence that NSP2 acts as a cofactor for
1872 the NSP4 serine protease. *Journal of Virology* **71**, 9313-9322.

1873 Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby
1874 JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM (2003).
1875 Antibody neutralization and escape by HIV-1. *Nature* **422**, 307-312.

1876 Weidman MK, Sharma R, Raychaudhuri S, Kundu P, Tsai W, Dasgupta A (2003). The
1877 interaction of cytoplasmic RNA viruses with the nucleus. *Virus Research* **95**, 75-85.

1878 Weiland E, Wiczorek-Krohmer M, Kohl D, Conzelmann KK, Weiland F (1999). Monoclonal
1879 antibodies to the GP5 of porcine reproductive and respiratory syndrome virus are more
1880 effective in virus neutralization than monoclonal antibodies to the GP4. *Veterinary
1881 Microbiology* **66**, 171-186.

1882 Welch SK, Jolie R, Pearce DS, Koertje WD, Fuog E, Shields SL, Yoo D, Calvert JG (2004).
1883 Construction and evaluation of genetically engineered replication-defective porcine
1884 reproductive and respiratory syndrome virus vaccine candidates. *Veterinary Immunology
1885 and Immunopathology* **102**, 277-290.

1886 Wensvoort G, Terpstra C, Pol JM, ter Laak EA, Bloemraad M, de Kluyver EP, Kragten C, van
1887 Buiten L, den Besten A, Wagenaar F, et al (1991). Mystery swine disease in The
1888 Netherlands: the isolation of Lelystad virus. *The Veterinary Quarterly* **13**, 121-130.

1889 Wieringa R, de Vries AA, Raamsman MJ, Rottier PJ (2002). Characterization of two new
1890 structural glycoproteins, GP(3) and GP(4), of equine arteritis virus. *Journal of Virology*
1891 **76**, 10829-10840.

1892 Wieringa R, de Vries AA, Rottier PJ (2003). Formation of disulfide-linked complexes between
1893 the three minor envelope glycoproteins (GP2b, GP3, and GP4) of equine arteritis virus.
1894 *Journal of Virology* **77**, 6216-6226.

1895 Wieringa R, de Vries AA, van der Meulen J, Godeke GJ, Onderwater JJ, van Tol H, Koerten
1896 HK, Mommaas AM, Snijder EJ, Rottier PJ (2004). Structural protein requirements in
1897 equine arteritis virus assembly. *Journal of Virology* **78**, 13019-13027.

1898 Wilson L, McKinlay C, Gage P, Ewart G (2004). SARS coronavirus E protein forms cation-
1899 selective ion channels. *Virology* **330**, 322-331.

1900 Wissink EH, Kroese MV, Maneschijn-Bonsing JG, Meulenberg JJ, van Rijn PA, Rijsewijk FA,
1901 Rottier PJ (2004). Significance of the oligosaccharides of the porcine reproductive and
1902 respiratory syndrome virus glycoproteins GP2a and GP5 for infectious virus production.
1903 *Journal of General Virology* **85**, 3715-3723.

1904 Wissink EH, Kroese MV, van Wijk HA, Rijsewijk FA, Meulenberg JJ, Rottier PJ (2005).
1905 Envelope protein requirements for the assembly of infectious virions of porcine
1906 reproductive and respiratory syndrome virus. *Journal of Virology* **79**, 12495-12506.

1907 Wissink EH, van Wijk HA, Kroese MV, Weiland E, Meulenberg JJ, Rottier PJ, van Rijn PA
1908 (2003). The major envelope protein, GP5, of a European porcine reproductive and
1909 respiratory syndrome virus contains a neutralization epitope in its N-terminal
1910 ectodomain. *Journal of General Virology* **84**, 1535-1543.

1911 Wootton S, Koljesar G, Yang L, Yoon KJ, Yoo D (2001). Antigenic importance of the carboxy-
1912 terminal beta-strand of the porcine reproductive and respiratory syndrome virus
1913 nucleocapsid protein. *Clinical and Diagnostic Laboratory Immunology* **8**, 598-603.

1914 Wootton S, Yoo D, Rogan D (2000). Full-length sequence of a Canadian porcine reproductive
1915 and respiratory syndrome virus (PRRSV) isolate. *Archives of Virology* **145**, 2297-2323.

1916 Wootton SK, Nelson EA, Yoo D (1998). Antigenic structure of the nucleocapsid protein of
1917 porcine reproductive and respiratory syndrome virus. *Clinical and Diagnostic Laboratory*
1918 *Immunology* **5**, 773-779.

1919 Wootton SK, Rowland RR, Yoo D (2002). Phosphorylation of the porcine reproductive and
1920 respiratory syndrome virus nucleocapsid protein. *Journal of Virology* **76**, 10569-10576.

1921 Wootton SK, Yoo D (2003). Homo-oligomerization of the porcine reproductive and respiratory
1922 syndrome virus nucleocapsid protein and the role of disulfide linkages. *Journal of*
1923 *Virology* **77**, 4546-4557.

1924 Wu WH, Fang Y, Farwell R, Steffen-Bien M, Rowland RR, Christopher-Hennings J, Nelson EA
1925 (2001). A 10-kda structural protein of porcine reproductive and respiratory syndrome
1926 virus encoded by orf2b. *Virology* **287**, 183-191.

1927 Wu WH, Fang Y, Rowland RR, Lawson SR, Christopher-Hennings J, Yoon KJ, Nelson EA
1928 (2005). The 2b protein as a minor structural component of PRRSV. *Virus Research*.

- 1929 Wurm T, Chen H, Hodgson T, Britton P, Brooks G, Hiscox JA (2001). Localization to the
1930 nucleolus is a common feature of coronavirus nucleoproteins, and the protein may disrupt
1931 host cell division. *Journal of Virology* **75**, 9345-9356.
- 1932 Xue Q, Zhao YG, Zhou YJ, Qiu HJ, Wang YF, Wu DL, Tian ZJ, Tong GZ (2004). Immune
1933 responses of swine following DNA immunization with plasmids encoding porcine
1934 reproductive and respiratory syndrome virus ORFs 5 and 7, and porcine IL-2 and
1935 IFNgamma. *Veterinary Immunology and Immunopathology* **102**, 291-298.
- 1936 Yang L, Frey ML, Yoon KJ, Zimmerman JJ, Platt KB (2000). Categorization of North American
1937 porcine reproductive and respiratory syndrome viruses: epitopic profiles of the N, M,
1938 GP5 and GP3 proteins and susceptibility to neutralization. *Archives of Virology* **145**,
1939 1599-1619.
- 1940 Yang SX, Kwang J, Laegreid W (1998). Comparative sequence analysis of open reading frames
1941 2 to 7 of the modified live vaccine virus and other North American isolates of the porcine
1942 reproductive and respiratory syndrome virus. *Archives of Virology* **143**, 601-612.
- 1943 Yang Y, Zhang J (1999). An experimental study on the endurance of immunologic memory of
1944 intradermal micro-injection with rabies vaccine and boosting immune effect. *Journal of*
1945 *Epidemiology* **9**, 209-215.
- 1946 Yoo BJ, Spaete RR, Geballe AP, Selby M, Houghton M, Han JH (1992). 5' end-dependent
1947 translation initiation of hepatitis C viral RNA and the presence of putative positive and
1948 negative translational control elements within the 5' untranslated region. *Virology* **191**,
1949 889-899.
- 1950 Yoo D, Wootton SK, Li G, Song C, Rowland RR (2003). Colocalization and interaction of the
1951 porcine arterivirus nucleocapsid protein with the small nucleolar RNA-associated protein
1952 fibrillarin. *Journal of Virology* **77**, 12173-12183.
- 1953 Yoon KJ, Zimmerman JJ, Swenson SL, McGinley MJ, Eernisse KA, Brevik A, Rhinehart LL,
1954 Frey ML, Hill HT, Platt KB (1995). Characterization of the humoral immune response to
1955 porcine reproductive and respiratory syndrome (PRRS) virus infection. *Journal of*
1956 *Veterinary Diagnostic Investigation* **7**, 305-312.
- 1957 Yoshii M, Kaku Y, Murakami Y, Shimizu M, Kato K, Ikeda H (2005). Genetic variation and
1958 geographic distribution of porcine reproductive and respiratory syndrome virus in Japan.
1959 *Archives of Virology*.

- 1960 Yoshii M, Okinaga T, Miyazaki A, Kato K, Ikeda H, Tsunemitsu H (2008). Genetic
1961 polymorphism of the nsp2 gene in North American type porcine reproductive and
1962 respiratory syndrome virus. *Archives of Virology* **153**, 1323-1334.
- 1963 Yuan S, Murtaugh MP, Faaberg KS (2000). Heteroclitite subgenomic RNAs are produced in
1964 porcine reproductive and respiratory syndrome virus infection. *Virology* **275**, 158-169.
- 1965 Yuan S, Murtaugh MP, Schumann FA, Mickelson D, Faaberg KS (2004). Characterization of
1966 heteroclitite subgenomic RNAs associated with PRRSV infection. *Virus Research* **105**, 75-
1967 87.
- 1968 Zeegers JJ, Van der Zeijst BA, Horzinek MC (1976). The structural proteins of equine arteritis
1969 virus. *Virology* **73**, 200-205.
- 1970 Zhang Y, Sharma RD, Paul PS (1998). Monoclonal antibodies against conformationally
1971 dependent epitopes on porcine reproductive and respiratory syndrome virus. *Veterinary*
1972 *Microbiology* **63**, 125-136.
- 1973 Zhou L, Zhang J, Zeng J, Yin S, Li Y, Zheng L, Guo X, Ge X, Yang H (2009). The 30-amino-
1974 acid deletion in the Nsp2 of highly pathogenic porcine reproductive and respiratory
1975 syndrome virus emerging in China is not related to its virulence. *Journal of Virology* **83**,
1976 5156-5167.
- 1977 Zhou YJ, An TQ, He YX, Liu JX, Qiu HJ, Wang YF, Tong G (2006). Antigenic structure
1978 analysis of glycosylated protein 3 of porcine reproductive and respiratory syndrome
1979 virus. *Virus Research* **118**, 98-104.
- 1980 Zhou YJ, Hao XF, Tian ZJ, Tong GZ, Yoo D, An TQ, Zhou T, Li GX, Qiu HJ, Wei TC, Yuan
1981 XF (2008). Highly virulent porcine reproductive and respiratory syndrome virus emerged
1982 in China. *Transboundary and Emerging Diseases* **55**, 152-164.
- 1983 Ziebuhr J, Snijder EJ, Gorbalenya AE (2000). Virus-encoded proteinases and proteolytic
1984 processing in the Nidovirales. *Journal of General Virology* **81**, 853-879.
- 1985
- 1986

FIGURES LEGENDS

1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001

Figure 1. Schematic representation of the PRRSV particle. The location of the structural proteins: GP_{2a}, E, GP₃, GP₄, GP₅, M and N (encoded by ORFs 2-7) are shown. The virion possesses a non-segmented single-strand RNA genome, enclosed into a nucleocapsid protein (N), yielding a helicoidal capsid structure. The N protein is the sole component of the viral capsid and interacts with itself through covalent and non-covalent interactions (homodimer). The major envelope viral protein (GP₅) forms a heterodimer structure with the membrane non-glycosylated protein (M) which dominates the virion surface. The minor structural proteins (GP_{2a}, E, GP₃ and GP₄) are incorporated into virions as a multimeric complex. The minor structural viral proteins multimeric complex also interacts with the GP₅-M heterodimer (not illustrated). Although the GP₃ is a structural viral protein, it has been reported once that the GP₃ is a non-structural and secreted viral protein (which suggest that it could be a strain dependent phenomenon).

Figure 2. Schematic representation of the PRRSV genome organization and replication. The replicase 1a and 1ab polyproteins (pp1a and pp1ab) are expressed from the genomic viral RNA. The filled circle indicates the ribosomal frameshift site, and the filled box indicates the leader sequence. The structural proteins are expressed from a nested set of subgenomic mRNAs, RNAs 2-7, that contain a common 5' leader sequence. The pp1a is predicted to be cleaved at eight sites to form nine non-structural proteins (nsp): nsp1 α , nsp1 β , and nsp2 to nsp8. Proteolytic cleavage of the ORF1b gene portion of the pp1ab generates products nsp9 through nsp12. The processing of pp1a and pp1ab is mediated by accessory proteinases located in nsp1 (papain-like cysteine proteinases: PCP α and PCP β) and nsp2 (chymotrypsin-like cysteine protease: PL2pro);

2011 and the main serine proteinase located in nsp4 (the serine/3C-like proteinase: 3CLpro). PCP α
2012 and PCP β are responsible for the autoproteolytic release of the nsp1 α and nsp1 β , respectively. In
2013 addition nsp1 contain zinc-finger motif (ZF) required for subgenomic mRNA transcription.
2014 Predicted catalytic dyads of both PCP domains and the estimated positions of their respective
2015 nsp1 α /nsp1 β and nsp1 β /nsp2 cleavage site are illustrated.

2016

2017 **Figure 3. PRRSV N protein schematic model of the North American isolates.** The numbers
2018 identify the amino acids positions covered by each domain. **I-V**: five domains of antigenic
2019 importance (30-52; 37-52; 52-69; 69-112 and 112-123); 23-Cys: identifies the location of the
2020 conserved cysteine residue involved in the intermolecular disulfide bonds N protein homodimer
2021 formation; 120-Ser: identifies the location of a serine residue that is a phosphorylation target;
2022 NLS-1: Nuclear localisation signal- 1 or cryptic NLS; NLS-2: Nuclear localisation signal -2 or
2023 functional NLS; NoLS: Nuclear localisation signal sequence. This figure is adapted from
2024 Rowland and Yoo, 2003.

2025

2026 **Figure 4. Functional and structural domains of the PRRSV GP₅ protein of North**
2027 **American isolates.** The numbers identify the amino acids positions covered by each domain.
2028 Conserved (black) and non-conserved (grey) glycolysation sites: N30, N34, N44 and N51; the
2029 conserved cysteine residue involved in the formation the disulfide bond between GP₅ and M is
2030 illustrated: 48-Cys; signal sequence: 1-32; ectodomain: 33-63; transmembrane region: 64-134;
2031 endodomain: 135-200; Major neutralizing epitope: 36-52; Hypervariable immunodominant non-
2032 neutralizing epitope A (decoy epitope): 27-30; Conserved non-immunodominant neutralizing

2033 epitope B: 37-45; Variable regions 57-70 and 121-130; Conserved regions: 41-56, 71-120 and
2034 131-200.

Table 1. PRRSV structural and non-structural proteins characteristics and functions.

Proteins	Genes	Amino acids lengths		Characteristics and functions
		EU strains	NA strains	
nsp1	ORF1a	385	383	Non-structural multifunctional regulatory protein (processing, transcription, virion biogenesis); proteolytic activities; IFN inhibition.
nsp2		861	980	Non-structural, the largest PRRSV replicative protein; the major genetic differences between NA and EU PRRSV strains; ideal marker for monitoring the genetic variation and for developing differential diagnostic tests; proteolytic activities; IFN inhibition.
nsp3		447	446	Non-structural proteins; proteolytic activities; nsp4: IFN inhibition.
nsp4		203	204	
nsp5		170	170	
nsp6		16	16	
nsp7		269	259	
nsp8		45	45	
nsp9	ORF1b	645	640	Non-structural proteins; virus transcription and replication; nsp9: RNA-dependent RNA polymerase and NTPase; nsp10: helicase; nsp11: IFN inhibition;.
nsp10		442	441	
nsp11		224	223	
nsp12		152	153	
GP _{2a}	ORF2a	249	256	Minor structural protein; contain 2 two highly conserved putative N-linked glycosylation sites; essential for virus infectivity; incorporated into virions as a multimeric complex; viral attachment protein.
E	ORF2b	70	73	Minor unglycosylated and myristoylated structural protein; essential for virus infectivity; incorporated into virions as a multimeric complex; possesses ion-channel like properties and may function as a viroporin in the envelope.
GP ₃	ORF3	265	254	Minor structural protein, one of the most variable PRRSV proteins; highly glycosylated with potentially seven N-linked oligosaccharides; its membrane topology seems to be strains dependent; highly antigenic and may be involved in viral neutralization; essential for virus infectivity; incorporated into virions as a multimeric complex.
GP ₄	ORF4	183	178	Minor structural highly glycosylated protein (four N-linked glycosylation sites); essential for virus infectivity; key glycoprotein for formation of the multiprotein complex incorporated into virions; mediates interaction between multiprotein complex of the minor viral glycoproteins and GP ₅ ; viral attachment protein and may be involved in viral neutralization.
GP ₅	ORF5	201	200	Major structural, transmembrane protein with a variable number of potential N-glycosylation sites; the most variable structural proteins in the PRRSV genome with GP ₃ ; involved in virus neutralisation and protection; the covalent association of GP ₅ and M is crucial for virus assembly; involved in the entry of virus into the host cells and in the apoptosis phenomenon.
M	ORF6	173	174	Major unglycosylated structural protein which is the most conserved; play a key role in virus assembly and budding; GP ₅ -M heterodimerization is crucial for virus infectivity.
N	ORF7	128	123	Major unglycosylated, phosphorylated and structural protein; highly immunogenic and a suitable candidate for the detection of virus-specific antibodies and diagnosis of the disease; the sole component of the viral capsid and interacts with itself through covalent and non-covalent interactions; able to localize in the nucleus/nucleolus and interact with cellular transcription factor.

ORF: Open reading frames; EU: European PRRSV strains; NA: North American PRRSV strains.

Fig. 1





Fig. 2

Fig. 3




Fig. 4

